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UDP-sugars were identified as extracellular signaling molecules, assigning a new function to 
these compounds in addition to their well-defined role in intracellular substrate metabolism 
and storage. Previously regarded as an orphan receptor, the G protein-coupled receptor 
(GPCR) P2Y14 (GPR105) was found to bind extracellular UDP and UDP-sugars. Little is 
known about the physiological functions of this GPCR. To study its physiological role a gene-
deficient (KO) mouse strain expressing the bacterial LacZ reporter gene was used to monitor 
the physiological expression pattern of P2Y14. P2Y14 is mainly expressed in pancreas and 
salivary glands and in subpopulations of smooth muscle cells of the gastrointestinal tract, 
bronchioles, blood vessels and uterus. Among other phenotypical differences KO mice 
showed a significantly impaired glucose tolerance following oral and intraperitoneal glucose 
application. An unchanged insulin tolerance points towards an altered pancreatic islet 
function. Transcriptome analysis of pancreatic islets showed that P2Y14 deficiency 
significantly changed expression of components involved in insulin secretion. Insulin 
secretion tests revealed a reduced insulin release from P2Y14-deficient islets highlighting 
P2Y14 as a previously unappreciated modulator of proper insulin secretion. 
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1 INTRODUCTION 
In the regulation of virtual all physiological functions of the human organism, G protein-
coupled receptors (GPCR) play a central role. GPCR are involved in the perception of 
environmental stimuli like light, smell or taste as well as in endocrine and neuronal signaling 
controlling both cognitive functions and unconscious homeostatic processes. This includes 
regulation of nutrient uptake, storage and utilization and energy balance, processes that are 
subject to great attention in metabolic disorder research. With their genes comprising 3% of 
the entire genome, GPCR form one of the largest protein families (1,2). These over 800 genes 
can be classified due to structural and physiological aspects. However, the recently used 
GRAFS classification system groups the receptors in following five classes using 
phylogenetic features: Glutamate (G), Rhodopsin (R), Adhesion (A), Frizzled/Taste2 (F), and 
Secretin (S) receptors (3). The most studied rhodopsin receptor class comprises about 700 
GPCR, including nearly 400 odorant receptors. 
Despite their activation by structurally different ligands and their high functional diversity 
every GPCR is shown to consist of seven transmembrane helices which are connected by 
three intracellular and three extracellular loops. Whereas the extracellular N-terminus is in 
charge of ligand binding, the intracellular C-terminus interacts with a heterotrimeric G protein 
that determines the downstream signaling. Upon ligand binding conformational changes in the 
receptor result in the exchange of GDP to GTP and dissociation of the α-subunit and the βγ-
dimer of the G-protein complex. Both are able to activate further effectors (4). Usually G 
proteins are referred to by the isoform of their α-subunit. So far more than 20 isoforms have 
been identified which can be assigned to four major groups: Gs, Gi/o, Gq/11 and G12/13. Gs 
coupling stimulates, Gi/o coupling inhibits the adenylyl cyclase activity resulting in elevation 
or decrease of intracellular cAMP levels, respectively. Activation of Gq/11 subunit leads to 
generation of second messengers diacylglycerol (DAG) and inositol (1,4,5)-trisphosphate 
(IP3) via activation of phosholipase Cβ (PLCβ) (5). G12/13 subunit mediates its signaling by 
stimulation of Rho guanine-nucleotide exchange factors. However, βγ-dimers as well are 
shown to affect the activity of ion channels, RGS proteins, and certain types of adenylyl 
cyclases and phospholipases C (6). 
1.1  P2Y14 discovery as an orphan GPCR 
Although the physiological function is known for many members of the family of GPCR 
and about 36% of currently approved drugs act via their activation (7), functional ligands have 
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not been identified yet for more than one hundred so-called orphan receptors. These receptors 
were predicted from DNA sequences which share sequence motifs characteristic of GPCR 
using homology screening techniques, such as degenerate polymerase chain reaction and low-
stringency hybridization (8,9). In a classic approach, bioactive substances, that were 
potentially GPCR ligands, were used to identify the receptor. Cloning methods evolved in the 
late 1980’s and allowed to test possible ligands and tissue extracts on orphan GPCR expressed 
in heterologous cell systems. The serotonine 5-HT1A receptor (10) and the dopamine D2 
receptor (11) were the first deorphanized GPCR. Using this so-called reverse pharmacology 
approach most of the identified GPCR were assigned to their endogenous agonists by 
academic research groups and pharmaceutical companies engaged in large-scale 
deorphanization efforts (9). 
Thus, one of the studies discovered P2Y14 (formerly referred to as KIAA0001, VTR 15-20, 
GPR 105) as a GPCR. KIAA0001 was initially cloned from a human myeloid cell line and 
shows several attributes (e.g. seven transmembrane domains, consensus sequences for protein 
kinase phosphorylation, extracellular N-terminus) characteristic for GPCR (12,13). As known 
for diverse GPCR, the human P2Y14 gene as well shows genomic clustering with other 
GPCR. P2Y14 is co-localized with P2Y12, P2Y13, GPR87 and GPR171 on the long arm of the 
chromosome 3 (14). 
1.2 P2Y14 as a member of the P2Y12-like receptor group 
P2Y14 belongs to the P2Y12–like receptor group within the family of rhodopsin-like 
receptors. P2 receptors are activated by extracellular purine and pyrimidine nucleotides and 
are subdivided into two main families, the P2X ionotropic ligand-gated ion channel receptors 
and the P2Y metabotropic GPCR. On the basis of their amino acid sequences the eight 
identified P2Y receptors form two distinct subgroups. The P2Y1 group includes P2Y1, P2Y2, 
P2Y4, P2Y6, and P2Y11, whereas the P2Y12 group contains the P2Y12, P2Y13 and P2Y14.  
Based on structural similarity and phylogenetic aspects the P2Y12–like receptor group 
comprises, additional to the above mentioned P2Y12-14 receptors, the orphan receptors 
GPR34, GPR82, GPR87, and GPR171 (Fig. 1). Phylogenetic analyses of this receptor family 
show the presence of these GPCR in cartilaginous and bony fishes suggesting their existence 
for more than 450 million years. The high degree of structural conservation within the P2Y12-
like receptor group is a sign of selective constraint on the sequences during the evolution and 
emphasizes the importance of this group in regulating physiological functions (14). 
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Figure 1 Phylogenetic clustering of human P2Y receptors. 
Based on phylogenetic and structural aspects the P2Y12-like receptor group forms a distinct subgroup 
within the P2Y receptors (14).  
The most studied ADP receptor P2Y12 plays a significant role in platelet aggregation and 
several antithrombotic drugs like clopidogrel, ticagrelor and prasugrel target this GPCR in 
order to prevent myocardial infarction and strokes. Patients with inactivating mutations in 
P2Y12 were shown to have bleeding disorders (15,16). A number of groups characterized the 
role of P2Y13 in cholesterol metabolism (17-19) and several ongoing studies discuss its 
influence in bone development (20-22). Knockout (KO) mouse studies revealed the 
involvement of the orphan GPR82 in energy homeostasis, and indeed, SNP variants in GPR82 
could be associated with lower BMI in a human population (23). However, only little is 
known about the physiological relevance of the other members of the P2Y12-like receptor 
group.  
1.3 Ligand-binding studies and G-protein coupling of P2Y14 
In the past years, a number of P2Y12-like receptors were assigned to their endogenous 
agonists, including various substance classes like nucleotide derivates and lipids (24-27). 
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Thus, P2Y12-like receptor family seems to have high ligand promiscuity showing broad 
pharmacological profiles as known for other GPCR receptor groups like trace amine-
associated receptors (28,29) and MAS-related GPCR (9). 
In 2000, P2Y14 was deorphanized using the reverse pharmacology approach. Chambers et al. 
(30) screened several GPCR, expressed in a heterologous yeast cell system, against a huge 
library of potential GPCR agonists and found UDP-glucose to activate P2Y14. This was an 
interesting finding, since UDP-glucose was previously only known as a glucosyl donor in 
glycogen biosynthesis. Several closely related sugars like UDP-galactose, UDP-glucuronic 
acid and UDP-N-acetylglucosamine showed agonistic activity on this GPCR as well. These 
results were verified in mammalian HEK-293 cell both, transiently and stably expressing the 
P2Y14 gene and the promiscuous G protein α-subunit Gα16 (30). 
Chambers (30) as well studied the G-protein coupling of P2Y14 in GTPγS radioactive assays. 
UDP-glucose promoted GTPγS binding to endogenous G proteins could be blocked by pre-
incubation of mammalian cells with pertussis toxin, indicating that P2Y14 mediates the 
inhibition of adenylyl cyclase via coupling to Gαi subunits. Fricks (31), Moore (32), Ko (33) 
and other colleagues used a more robust experimental approach to investigate the signal 
transduction pathway of this GPCR. Thus, a chimeric Gαqi4 subunit was coexpressed with 
P2Y14 to redirect the Gi signaling to the PLC-β pathway following Ca2+ response. These 
experiments confirmed the preferred Gi coupling of P2Y14 stimulated with UDP-glucose and 
other UDP-activated sugars.  
In more recent studies, UDP alone was controversially discussed as agonist for P2Y14. No 
agonistic activity of UDP and other P2Y receptor nucleotide ligands was seen in GTPγS 
binding assays of HEK-293 cells stably expressing P2Y14 (30). Scrivens et al. could not 
detect any effect of UDP on forskolin-stimulated cAMP levels in isolated human neutrophils 
and T-lymphocytes (34,35) and similar results were reported by Ko and his colleagues in 
COS-7 cells transiently co-expressing the human P2Y14 and the Gqi5 protein (33). However, 
using different human receptor mutants of P2Y14 Ault and Broach tested antagonistic activity 
of UDP on UDP-glucose-mediated receptor stimulation (36). Subsequent analyses specified 
that the detected UDP antagonism was competitive (31). On the other hand, further studies 
with classic cAMP inhibition assays (37) and nonconventional methods like cellular 
impedance functional assays (38) described UDP as a potent agonist on human P2Y14. 
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1.4 Physiological relevance of P2Y14 
Tissue distribution is often used to anticipate a possible function of a novel protein. P2Y14 
mRNA expression and Northern blot analyses showed a widespread expression pattern 
including high expression levels in placenta, adipose tissue, stomach and intestine and 
moderate levels in spleen, lung, heart and different brain regions (32,39). P2Y14 was also 
detected in immune cells, such as B- and T-lymphocytes, neutrophils, dendritic cells, 
astrocytes, and microglia (32,34,35,40,41). Based on the high prevalence of this GPCR in the 
immune system, previous studies focused on elucidating the involvement of P2Y14 in immune 
and inflammatory responses. Indeed, expression of P2Y14 was upregulated following 
inflammatory injury (42) and similar results were shown by in vivo treatment with 
lipopolysaccharide for rat brain and spleen (13,32). P2Y14 was reported to mediate mast cell 
degranulation (43) and dendritic cell maturation by intracellular Ca2+ mobilization (41). 
Further, Kook et al. (44) described protective effects of P2Y14 signaling pathway in response 
to radiation. 
Functional studies regarding the high expression levels in the gastrointestinal tract revealed an 
influence of P2Y14 in gastric motility function, however Bassil et al. demonstrated that some 
effects of UDP-glucose were independent of P2Y14 signaling (45). 
A very recent study identified P2Y14 as one of the 293 GPCR expressed in human pancreatic 
islets (46). It is known that GPCR play an important role in regulation of hormone secretion 
from pancreatic islets. Depending on their presence in one of the major islet cells (α-, β-, or δ-
cells) the certain GPCR have a different impact on the release of glucagon, insulin or 
somatostatin (46). Interestingly, only a few GPCR targeting drugs (e.g. GLP-1 receptor 
agonist exenatide) are approved for the therapy of type 2 diabetes (46). For several nucleotide 
receptors (e.g. P2Y1, P2Y6, P2Y13) the influence on the secretion of insulin and glucagon has 
been shown (46). However, the particular cell type within the pancreatic islet that expresses 
P2Y14 and its relevance in hormone secretion has not been studied yet. 
Considering the fact, that GPCR are related to several endocrine disorders and even malignant 
diseases (47) and that GPCR are highly relevant as drug targets, previous P2Y14 studies 
showed enormous potential of this GPCR for future therapeutic applications, but the 
physiological relevance of P2Y14 still remains to be defined in more detail. 
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2 OBJECTIVES 
The UDP-glucose receptor P2Y14 is a member of the P2Y12-like receptor group. Although 
UDP-sugars and UDP were identified as endogenous agonists of this GPCR the literature is 
controversial regarding their physiological role. Further, the physiology of P2Y14 is not 
understood in detail. Therefore, this study aimed at the physiological characterization of 
P2Y14 function in vivo. Because high expression was found in the gastrointestinal system, the 
main focus of this study was directed on exploring a possible role of P2Y14 in the regulation 
of nutrient uptake and energy metabolism. Taking advantage of a P2Y14-deficient and LacZ-
reporter mouse model the following questions were addressed: 
1. Where is P2Y14 expressed in mice? 
2. Does P2Y14 deficiency have a major impact on mouse ontogenesis? 
3. Does P2Y14 influence smooth muscle function?  
4. Does and how does P2Y14 affect the regulation of glucose homeostasis? 
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3 EXPERIMENTAL PROCEDURES 
3.1 Materials 
If not stated otherwise, all standard substances were obtained from Sigma-Aldrich 
(Taufkirchen, Germany), Merck (Darmstadt, Germany), and C. Roth GmbH (Karlsruhe, 
Germany). Cell culture material was purchased from Sarstedt (Nümbrecht, Germany). 
3.2 Mice 
All mice were maintained in a specific pathogen-free barrier facility on a 12-h light/12-h dark 
cycle with ad libitum access to water and food. Experiments were performed according to the 
accepted standards of animal care and were approved by the respective regional government 
agency of the State of Saxony, Germany (T27/11; T46/12; T07/13). 
3.2.1 Generation of P2Y14-deficient mice  
P2Y14-KO mice were generated at TAKEDA Ltd. (Cambridge, United Kingdom) by 
targeted disruption of the mouse P2Y14 locus and ES-cell blastocyst injection. Thus, most part 
of the coding region of P2Y14 was exchanged by a ß-galactosidase cassette harbouring an 
internal ribosome entry site (IRES) followed by a loxP-floxed neomycin cassette (Fig. 2). 
 
Figure 2 Generation of a P2Y14-deficient mouse strain and P2Y14 qPCR design. 
P2Y14-deficient mice were generated at TAKEDA Ltd.. The coding sequence was partly replaced by 
an ECMV-IRES / ß-galactosidase cassette followed by a loxP-floxed neomycin selection cassette. The 
neomycin cassette was removed by breeding with EIIa-Cre mice and successful removal was verified 
by PCR. For qPCR a primer pair matching to exons 1 and 2 was designed. Genotyping of mice was 
performed as described under 3.2.2 with primers indicated as: for, rev and ß-gal s. 
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Neomycin-resistant ES cells were screened for homologous recombination. Positive ES cell 
clones were injected into blastocysts. Chimeric offspring was fertile and crossed into a 129S6 
background. These mice were crossed with EIIa-Cre mice (C57Bl/6 strain) to remove the 
neomycin cassette. Correct deletion was verified by PCR and sequencing of the locus. The 
resulting KO animals were bred with 129S6 animals and all studies were done on a mixed 
C57BL/6 x 129S6 background with predominance of 129S6. For experiments WT and KO 
littermates from intercrossed WT and KO parents were used. 
3.2.2 Genotyping 
Genotyping of mice was carried out by PCR with the following primers: 
ß-gal sense: 5’-AGAAGGCACATGGCTGAATATCGA-3’ 
forward: 5`-AGCTGCCGGACGAAGGAGACCCTGCTC-3’ 
reverse: 5’-GGTTTTGGAAACCTCTAGGTCATTCTG-3’ 
in two separate PCR reactions (Fig. 2): forward/reverse to amplify WT allele and ß-gal 
sense/reverse to amplify KO allele. The PCR conditions were 95°C for 3 minutes followed by 
35 cycles with 45 sec 95°C, 60°C 30 sec and 72°C for 1 min and a final amplification step of 
72°C for 10 min. Amplification of the WT allele and the KO allele resulted in 180-bp and 
400-bp fragments, respectively. PCR products were separated via gel electrophoresis on a 2% 
agarose gel, stained with ethidium bromide, and visualized by ultraviolet illumination. 
3.3 Basic characterization of P2Y14-deficient mice 
3.3.1 Morphology 
Three-month-old mice were inspected for differences in breeding, growth, weight and 
morphology. Heterozygous females were bred with heterozygous males to document the litter 
genotype distribution. Body and tail lengths of mice were measured. Animals were monitored  
for morphological abnormalities during coat, teeth and limb development. Organs were 
removed and weighed.  
3.3.2 Quantitative expression analysis 
Several tissues were removed from 3 WT and 3 KO mice and RNA was isolated using 
TRIZOL (Sigma-Aldrich, Taufkirchen, Germany) according to the manufacturer’s 
instructions. RNA quantity was measured with a spectrophotometer (Nanodrop ND 1000, 
NanoDrop products, Wilmington, USA) and RNA quality was controlled by gel 
electrophoresis. For quantitative real time PCR (qPCR) 1 µg of total RNA was reversely 
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transcribed (Superscript II RT, Invitrogen, Karlsruhe, Germany) using oligo-dT primers. 
qPCR was performed by Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen) 
according to manufacturer’s instructions. Primers were designed for the intron-flanking exons 
1 and 2 sequences (Fig. 2) to exclude genomic contaminations (sense: 5’-
GAAGCCAGACGTGAAGGAGTT-3’; antisense: 5’-CAGGAATCTCAAAGGCAAGCT-3’) 
resulting in a 156-bp product. qPCR was performed with the MX 3000P instrument (Agilent 
Technologies GmbH, Boeblingen, Germany) using the following protocol: 2 min at 50 °C, 2 
min at 95 °C, 40 cycles of 15 s at 95 °C and 30 s at 60 °C. A product dissociation curve was 
recorded to verify the presence of a single amplicon. Threshold cycle (Ct) values were 
determined during the exponential increase of the product in the PCR. After normalization to 
the house keeping gene ß2-microglobulin calculated ∆Ct values were used to determine the 
relative expression of P2Y14. 
3.3.3 LacZ reporter gene assay 
Tissue samples of several organs were prepared from WT and KO mice, covered in Tissue-
Tek® (Sakura, Torrance, CA, USA) and snap frozen in liquid nitrogen. The organs were 
cryosectioned (10 µm) and fixed in acetone-methanol (1:1) solution. Sections were incubated 
with X-Gal staining solution (500 µg/ml X-gal in 3 mM potassium ferricyanide, 3 mM 
potassium ferrocyanide, 150 mM NaCl and 2 mM MgCl2 diluted in 0.45 mM HEPES buffer, 
pH 7.4) at 30 °C overnight to detect the expression of the LacZ reporter gene via ß-
galactosidase activity. Following, nuclear fast red staining was performed. 
3.3.4 Laboratory chemistry / histology 
Serum levels of electrolytes, metabolites, enzymes and hormones were analyzed in three-
month-old WT and KO mice according to the guidelines of the German Society of Clinical 
Chemistry and Laboratory Medicine, using a Hitachi PPE-Modular analyzer (Roche 
Diagnostics, Mannheim, Germany). Blood cell counting from EDTA blood samples was 
performed automatically (ScilVet abc; Scil corporation, Viernheim, Germany). Histological 
slices (5 μm) were prepared from organs being fixed in 4% formaldehyde solution and 
embedded in paraffin wax. Slices were stained with H&E. 
3.3.5 Behavioral tests 
The open field test was performed as reported previously (48) using automated measuring 
technology (TSE Systems, Bad Homburg, Germany). Activity of mice was recorded for a 
period of 5 min. In a hot plate test (Hot Plate 602001, TSE) the elapsed time until the first 
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reaction of the mice to the heat stimulus (52°C) was recorded. As endpoints shaking or licking 
of one of the hind paws or jumping off the analgesia meter were used. 
3.3.6 Assessment of hemodynamic parameters 
Blood pressure and pulse were determined by non-invasive tail-cuff method using the BP-
2000 Blood Pressure Analysis SystemTM (Visitech Systems, USA). Following manufacturer’s 
instructions, mice were trained to the procedure each day for at least 5 days prior to the actual 
experiment. After the training period 10 measurements per day of each mouse on 5 
consecutive days were performed. Systolic blood pressure, diastolic blood pressure, mean 
arterial pressure, and pulse were calculated from daily experiments for each mouse and mean 
out of 10 animals per group was determined. 
3.4 Smooth muscle function 
3.4.1 Gastrointestinal transit experiments 
A gastrointestinal emptying test was performed by oral application of 200 µl dye-labeled 
non-absorbable liquid dextran blue (20 mg/ml) to mice. Faeces were collected separately for 
each mouse hourly for 8 hours, vortexed with 300 µl phosphate buffered saline (PBS) and 
centrifuged at 13,000 rpm for 10 min. The amount of hourly excreted dextran blue was 
measured photometrical at 620 nm in supernatants. Mice that showed no excretion for at least 
2 hours were excluded from the experiment. The sum of totally excreted dextran blue was set 
100% and the relative expulsion of dextran blue was compared hourly between the WT and 
KO mice. 
3.4.2 Gastrointestinal contractility studies 
For contractility studies mice were sacrificed by cervical dislocation. The intestine from 
mice was harvested and placed in ice-cold Krebs-Ringer buffer (KRB, 117 mM NaCl, 4.7 
mM KCl, 1.2 mM MgCl2, 1.2 mM NaH2PO4, 25 mM NaHCO3, 2.5 mM CaCl2, 11.5 mM 
glucose, pH 7.4). One cm long equal segments of intestine were placed in 50-ml organ baths 
(37 °C) containing KRB solution and continuously gassed with 95% O2 and 5% CO2. To 
record the contractile activity, each intestine segment was connected to an isometric force 
transducer (MLT0201 Force Transducer; ADInstrumends GmbH, Spechbach, Germany). The 
basal tension was set to 10 mN. Intestine segments that did not show spontaneous activity 
were excluded from the experiment. After a 30 min equilibration phase the effects of 100 µM 
UDP-glucose and 100 µM carbachol (positive control) were tested. Each stimulation period 
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was monitored for at least 10 min. Intestine segments were washed three times after each 
stimulation period. Several parameters like mean muscle tension, average tension maximum 
and minimum, average amplitude, rate of contractions and the area under the curve were 
analyzed using Lab Chart software (ADInstruments). Data were normalized to recorded 
spontaneous activity and expressed in percentage. 
3.4.3 Airway responsiveness 
Lung resistance and dynamic compliance were measured by invasive plethysmography 
(emka TECHNOLOGIES, Paris, France) in response to inhaled UDP-glucose and 
methacholine (Sigma-Aldrich). Female mice were anesthetized (100 mg/kg ketamine and 10 
mg/kg xylazine; Bayer Leverkusen, Germany), intubated and mechanically ventilated at a 
tidal volume of 0.2 ml and a frequency of 150 breath/min. Baseline lung resistance, dynamic 
compliance, and responses to aerosolized saline (0.9% NaCl) were measured first, followed 
by responses to 100 µM aerosolized UDP-glucose and increasing doses (10 to 80 mg/ml) of 
aerosolized methacholine (49). 
3.5 Metabolic studies 
One-month-old mice were kept on standard (Ssniff M-Z: 5% sugar, 4.5% raw fat, 34% 
starch, 22% raw protein) or western (Ssniff EF R/M TD88137: 32.8% sugar, 21.2% raw fat, 
14.5% starch, 17.1% raw protein) type diet (Ssniff GmbH, Soest, Germany) for 3 months. 
During this period body-weight development was monitored weekly. All metabolic tests (see 
below) were performed in the same set of animals at the age of 4 months at the interval of one 
week.  
3.5.1 Glucose and insulin tolerance tests 
For glucose tolerance tests mice on a standard or a western type diet had been fasted 
overnight (15 h) and blood glucose levels were measured from tail vein blood before (0 min), 
20, 40, 60 and 120 min after oral application (80 mg) or intraperitoneal injection (2 mg/g 
body weight) of glucose. For insulin tolerance tests blood glucose levels were measured 
before (0 min) and 15, 30 and 60 min after intraperitoneal injection of human insulin (0.75 
U/kg body weight). Blood glucose levels were determined by using an automated blood 
glucose meter (FreestyleLite, Abbott Diabetes Care Ltd., Oxon, UK). 
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3.5.2 Insulin secretion tests 
For insulin secretion tests mice fasted overnight were injected intraperitoneally with 
glucose (2 mg/g body weight) and blood samples were taken before (0 min), 20, 40 and 60 
min after injection. Serum insulin concentrations were measured using an Ultra Sensitive 
Mouse Insulin Elisa Kit (Crystal Chem, Inc., Downers Grove, IL, USA) in accordance to 
manufacturer’s instructions. 
3.5.3 Morphometric analysis of pancreatic tissue 
Pancreata from 5 WT and 5 KO mice fed with western type diet were fixed in 4% 
formaldehyde and embedded in paraffin wax. Two longitudinal sections (4 µm) were 
generated every 100 µm of tissue. Each time, the first section was stained with H&E, the 
second immunostained for insulin with the avidin-biotin complex technique using anti-insulin 
monoclonal rabbit antibody (100 µg/ml, Cell Signalling, Millipore, Germany) and goat anti-
rabbit secondary antibody (7.5 mg/ml, Vector Laboraties, Biozol Diagnostica, Germany). 
Both sections were photographed with a Zeiss Axioimager Z1 microscope (Carl Zeiss Jena 
GmbH, Jena, Germany). Ten H&E stained sections per mouse were analyzed for number and 
area size of pancreatic islets using NIH ImageJ software (http://rsbweb.nih.gov/ij/). For 
determination of ß-cell area per islet the insulin-positive area of at least 50 islets per mouse 
was calculated using NIH ImageJ software and related to the total islet area of the investigated 
slides. 
3.6 Molecular and functional characterization of pancreatic islets 
3.6.1 Islet isolation 
Pancreatic islets were isolated as previously described (50-52). Briefly, mice were 
sacrificed by cervical dislocation and the pancreas was inflated by intraductal injection of ice-
cold DMEM media containing 0.2 mg/ml (1.08 Wünsch Units) Liberase TL Research Grade 
(Roche Diagnostics GmbH, Mannheim, Germany). Distended pancreas was digested by 
shaking in a 37 °C water bath for 17 minutes. Isolated islets were washed and picked under a 
stereomicroscope and incubated overnight at 37°C and 5% CO2 in RPMI-1640 media 
containing fetal bovine serum for insulin secretion studies.  
3.6.2 RNA-sequencing of pancreatic islets 
Total RNA from isolated pancreatic islets (10 male mice per genotype) was extracted by 
using TRIZOL (Sigma-Aldrich) according to the manufacturer’s instructions. RNA quantity 
21 
was measured by using a spectrophotometer (Nanodrop ND 1000). The RNA quality of all 
samples was further analyzed on the Agilent 2100 bioanalyzer using the RNA 6000 Nano 
Chip. cDNA libraries were generated using TruSeq RNA Sample Preparation Kits v2 
(Illumina, San Diego, CA, USA) according to the manufacturer’s protocol. Indexed islet 
libraries of good quality were pooled and used for sequencing on two flow cell lanes on 
Illumina HiScanSQ System. To confirm base calling correctness the raw data passed a quality 
check using FastQC software (http://www.bioinformatics.babraham.ac.uk/projects/fastqc). It 
revealed low PHRED-scale scores at the 3’ end of the 101 bp long reverse reads. These reads 
were trimmed to a size of 80 bp. Then, reads were assigned to the individual animals using the 
ligated adapter indices. Further, the samples proceeded filtering to trim the adapter sequences 
and remove low-quality reads which were shorter than 60 bp or contained more than five 
bases with a quality score below 15 (PHRED-scale). The paired-end reads were mapped to the 
reference mouse genome (July 2007 NCBI37/mm9) with Ensembl v66 annotations using 
Tophat 1.3.3. (53), which aligns reads using Bowtie (version 0.9.9). Mitochondrial reads and 
reads which did not map uniquely to a genome position were excluded. FPKM (fragments per 
kilobase of transcript per million mapped reads) values were calculated using Cufflinks 1.3.0 
(53,54). Analysis of differential expression was performed using DESeq software package 
(55). Only genes that were expressed at least in 10 animals were considered for analysis. 
Functional enrichment analysis of differentially expressed genes (P < 0.05) was determined 
using ToppGene Suite (56). 
3.6.3 Insulin release experiments from isolated islets 
For dynamic insulin secretion studies groups of 50 pancreatic islets were placed in a 
perifusion chamber and continuously perifused with KRB containing (all in mM) 115 NaCl, 
20 NaHCO3, 4.7 KCl, 1.2 KH2PO4, 1.2 MgSO4, 2.56 CaCl2, 10 HEPES pH 7.4, 0.1% bovine 
serum albumin, and 2.8 glucose for over 30 min (flow: 1 ml/min). After this equilibration 
phase islets were perifused for 30 min with low glucose (2.8 mM) to determine the basal 
insulin release and then challenged for 30 min with 16.7 mM glucose or 16.7 mM glucose 
plus 100 µM UDP-glucose. Samples of perifusate were collected every minute and insulin 
concentration was determined at indicated time points by Insulin AlphaLISA Kit (Perkin 
Elmer, Rodgau, Germany) following manufacturer’s instructions.  
For static incubation studies groups of 5 islets were placed in a 96-well plate. After a 30-
minute equilibration period in 200 µl KRB solution containing 2.8 mM glucose, pancreatic 
islets were stimulated with KRB solution containing either 2.8 mM or 16.7 mM glucose or 
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100 µM UDP-glucose in the presence of 16.7 mM glucose for 30 minutes. The supernatants 
were then collected for measurement of secreted insulin and islets were lysed in acid-ethanol 
to extract the residual islet insulin (50,51). Insulin concentrations were determined by Insulin 
AlphaLISA Kit (Perkin Elmer) following manufacturer’s instructions.  
3.7 Cell culture, transfection and functional assays 
For yeast experiments, the haploid Saccharomyces cerevisiae yeast strain MPY578t5 
(provided by Dr. Mark Pausch) was used for the expression of receptor constructs. Cells were 
transfected with plasmid DNA using electroporation as described (57). For expression in 
mammalian cells, COS-7 cells were grown in Dulbecco's modified Eagle's medium (DMEM 
supplemented with 10% (v/v) fetal bovine serum, 100 units/ml penicillin and 100 μg/ml 
streptomycin) at 37°C in a humidified 5% CO2 incubator. Transient transfection experiments 
of COS-7 cells with receptor constructs for cAMP inhibition measurements and for direct 
cAMP measurements (co-transfected with the chimeric G protein Gαsi5) were essentially 
performed as described previously (58). For measurements of dynamic mass redistribution 
(DMR) (59) HEK293 cells were grown in DMEM/F12 medium supplemented with 10% (v/v) 
fetal bovine serum, 100 units/ml penicillin and 100 μg/ml streptomycin at 37°C in a 
humidified 5% CO2 incubator and transiently transfected with the receptor constructs and 
split onto fibronectin-coated 384-well plates one day prior the assay. DMR measurements 
were performed with the Epic system (Corning, NY, US). 
For all transfection experiments the mouse and human P2Y14 coding sequence attached to an 
N-terminal hemagglutinin (HA) epitope and a C-terminal FLAG epitope was cloned into the 
mammalian expression vector pcDps. Additionally, for yeast experiments the mouse receptor 
was introduced into the yeast vector p416GPD. All control receptor plasmids were cloned 
with the described strategy and verified by Sanger sequencing. 
3.8 Statistical analyses and graphics 
If not stated otherwise statistical analyses were performed using Student’s t-test and 
graphics were designed using the GraphPad Prism 5 Software (GraphPad Software, Inc., La 
Jolla, CA, USA). 
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4 RESULTS 
4.1 Basic characterization of P2Y14-deficient mice 
To identify phenotypes related to the lack of P2Y14 function, this GPCR gene was 
removed by targeted deletion and replacement with a LacZ reporter gene (Fig. 2) in a mouse 
strain. Mice were kept in a SPF unit and under these conditions P2Y14 deficiency is 
compatible with life. The P2Y14-deficient mouse offspring was vital and fertile. No obvious 
differences in genotype distribution, breeding, growth, gross morphology and histology were 
detected on primary inspection compared to WT mice. However, comparison of the organ 
weights revealed a significantly higher spleen weight in P2Y14-KO mice (Table 1).  
Table 1 Body and organ weights of P2Y14-deficient in comparison to WT mice.  
Organs from three-month-old male and female mice were removed and weighed. Weight per organ is 
given in gram. Results are mean ± SD. ***P < 0.001. 
 
male female 
WT (n=19) KO (n=28) WT (n=24) KO (n=18) 
body weight (g) 25.08 ± 2.25 25.88 ± 1.96 20.9 ± 1.1 22.0 ± 1.34 
brain (g) 0.46 ± 0.03 0.46 ± 0.02 0.46 ± 0.01 0.46 ± 0.02 
heart (g) 0.13 ± 0.02 0.13 ± 0.01 0.1 ± 0.01 0.1 ± 0.01 
lung (g) 0.13 ± 0.02 0.16 ± 0.02 0.14 ± 0.01 0.14 ± 0.02 
liver (g) 1.1 ± 0.12 1.15 ± 0.12 0.82 ± 0.09 0.86 ± 0.11 
spleen (g) 0.07 ± 0.02 0.11 ± 0.03*** 0.07 ± 0.01 0.09 ± 0.02*** 
left kidney (g) 0.2 ± 0.03 0.22 ± 0.03 0.13 ± 0.01 0.13 ± 0.02 
right kidney (g) 0.2 ± 0.03 0.21 ± 0.03 0.13 ± 0.01 0.14 ± 0.02 
Moreover, the analysis of hemodynamic parameters displayed higher blood pressure and heart 
rate in mice lacking P2Y14 (Table 2). 
Table 2 Higher blood pressure and pulse in P2Y14-deficient mice. 
Blood pressure and pulse were determined by non-invasive tail-cuff method using the BP-2000 
Blood Pressure Analysis SystemTM (Visitech Systems, USA). Following manufacturer’s 
instructions, mice were trained to the procedure each day for at least 5 days prior to the actual 
experiment. After the training period 10 measurements per day of each mouse on 5 consecutive days 
were performed. Systolic blood pressure, diastolic blood pressure, mean arterial pressure, and pulse 
were calculated from daily experiments for each mouse and mean out of 10 animals per group was 
determined. Data shown as mean ± SEM. ** P < 0.01, *** P < 0.001; Student’s t-test. 
 WT (n=10) KO (n=10) 
mean arterial pressure (mmHg) 84.3 ± 1.0 93.8 ± 1.4*** 
systolic pressure (mmHg) 121.4 ± 1.0 129.8 ± 1.9** 
diastolic pressure (mmHg) 64.9 ± 1.3 75.7 ± 2.1*** 
pulse (min-1) 584 ± 15 654 ± 12** 
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In an open field test KO mice were significantly less active than the WT mice spending less 
time on locomotion and showing a reduced velocity (Table 3). However, no distinct 
behavioral phenotype could be detected on initial characterization. There was no difference 
between WT and KO mice in the hot plate test (Table 3). 
Table 3 Behavioral parameters. 
Open field test: 3-month-old male mice were tested in the setup. Recording and analysis was 
performed automatically. For hot plate test animals were set on a 52 °C heated plate and time until 
visible signs of pain were seen was measured. The table shows main parameters as mean ± SD.  *P < 
0.05; **P < 0.01; Student's t-test 
OPENFIELD TEST WT (n=16) KO (n=18) 
Total activity (s) 102.3 ± 38.3 74.1 ± 34.2* 
Total activity (%) 34.1 ± 12.8 24.7 ± 11.4* 
Counts 1068 ± 532 775 ± 386 
Velocity (cm s-1) 18.9 ± 5.4 15.1 ± 1.7* 
Distance (m) 23.1 ± 10.9 14.3 ± 6.7** 
Distance edges (m) 21.8 ± 9.8 13.2 ± 7.1 
Distance center (m) 1.3 ± 1.8 1.1 ± 1.9 
Distance corners (m) 12.6 ± 4.6 8.9 ± 4.2* 
HOT PLATE TEST WT (n=9) KO (n=12) 
time until signs of pain (s) 24 ± 5.5 21.6 ± 5 
 
Whole blood and serum samples from adult mice were analyzed by an automatic 
hemocytometer and at the Institute of Laboratory Medicine (Medical Faculty, University of 
Leipzig). Particular differences in hematological and laboratory parameters were not 
consistent and rather gender-specific (Tables 4 and 5). 
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Table 4 Hematology. 
Whole blood samples from three-month-old mice were analyzed by an automatic hemocytometer (ScilVet ABC; scil animal care company GmbH, Viernheim, 
Germany). Results are given as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t-test. 
standard diet male female 
WT (n=15) KO (n=11) WT (n=14) KO (n=19) 
WBC (10³ / mm³) 9.4 ± 2 10.4 ± 3.5 7.4 ± 1.4 9.3 ± 3.0 * 
RBC (10^6 / mm³) 8.4 ± 0.7 8.1 ± 1.3 8.6 ± 0.8 8.5 ± 0.8 
HGB (g / dl) 16.9 ± 1.1 16 ± 2.2 17 ± 1.2 17.9 ± 1.1 *  
HCT (%) 47.5 ± 4.2 44.6 ± 4.4 47.4 ± 4.4 48.7 ± 4.2 
PLT (10³ / mm³) 1175 ± 172 1248.5 ± 260.8 991.3 ± 105.8 1121.7 ± 157.5 * 
MCV (µm³) 56.7 ± 2.1 55.9 ± 8.7 55 ± 2.1 57.2 ± 1.9 ** 
MCH (pg) 20.3 ± 1.9 19.9 ± 2 19.9 ± 1.6 21.1 ± 1.6 
MCHC (g / dl) 35.8 ± 3.3 35.9 ± 4.1 36.1 ± 3.3 36.8 ± 2.7 
RDW (%) 13.3 ± 0.7 14.9 ± 0.6 *** 15.1 ± 0.7 13.5 ± 0.9 *** 
MPV (µm³) 5.2 ± 0.3 5.2 ± 0.3 5.3 ± 0.4 5.1 ± 0.3 
LYMPHOCYTES (%) 72.6 ± 4.7 70.3 ± 5.6 74.6 ± 5.7 74 ± 4.7 
MONOCYTES (%) 6.2 ± 0.6 6.7 ± 0.9 5.7 ± 1.2 5.4 ± 0.7 
GRANULOCYTES (%) 21.2 ± 4.6 23 ± 5 19.7 ± 4.8 20.6 ± 4.4 
LYMPHOCYTES (10³ / mm³) 6.8 ± 1.6 7.2 ± 2.3 5.5 ± 1.1 6.9 ± 2.4 
MONOCYTES (10³ / mm³) 0.5 ± 0.1 0.7 ± 0.3 0.4 ± 0.1 0.4 ± 0.2 
GRANULOCYTES (10³ / mm³) 2.1 ± 0.5 2.5 ± 1.3 1.6 ± 0.4 2 ± 0.6 * 
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 western diet male female 
WT (n=15) KO (n=15) WT (n=14) KO (n=13) 
WBC (10³ / mm³) 9.6 ± 1.8 8.3 ± 1.8 8 ± 1.9 8.5 ± 2.4 
RBC (10^6 / mm³) 11.3 ± 0.7 11.4 ± 1.3 10.8 ± 1.5 9.8 ± 1.7 
HGB (g / dl) 18.7 ± 1 18.3 ± 1.5 18.8 ± 2.5 16.5 ± 2.5 * 
HCT (%) 64 ± 3.1 61.6 ± 6 59.7 ± 6.9 57.7 ± 9.7 
PLT (10³ / mm³) 1031.3 ± 205.1 985 ± 162.4 958.3 ± 136.9 941 ± 100 
MCV (µm³) 57.2 ± 2.9 54.1 ± 2.3 ** 53 ± 13.8 59 ± 5 
MCH (pg) 16.6 ± 0.5 16.1 ± 0.9 17.3 ± 0.5 16.9 ± 0.8 
MCHC (g / dl) 29 ± 1.1 29.8 ± 1.0 * 30.5 ± 1.1 28.7 ± 2.2 * 
RDW (%) 14.1 ± 2.2 14.6 ± 1.2 13.1 ± 1.2 15.7 ± 1.2 *** 
MPV (µm³) 5.2 ± 0.4 5 ± 0.3 5 ± 0.3 5.2 ± 0.3 
LYMPHOCYTES (%) 72 ± 6.2 71.4 ± 6.5 72.3 ± 6.6 75.9 ± 5.8 
MONOCYTES (%) 5.9 ± 0.9 4.8 ± 0.7 ** 5.1 ± 1 4.3 ± 0.9 * 
GRANULOCYTES (%) 22.1 ± 6 23.8 ± 6.6 22.6 ± 5.9 19.8 ± 5.2 
LYMPHOCYTES (10³ / mm³) 6.9 ± 1.6 5.9 ± 1.6 5.7 ± 1.6 6.4 ± 1.8 
MONOCYTES (10³ / mm³) 0.5 ± 0.1 0.3 ± 0.1 *** 0.4 ± 0.1 0.3 ± 0.1 
GRANULOCYTES (10³ / mm³) 2.2 ± 0.6 2 ± 0.6 1.9 ± 0.5 1.8 ± 0.7 
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 Table 5 Laboratory screen. 
Four-month-old male and female WT and KO mice were subjected to analysis for cholesterol and TAG levels in lipoprotein fractions after a western diet and 
clinical chemistry parameters. Results are given as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, Student’s t-test. 
standard diet male female 
WT (n=14) KO (n=12) WT (n=15) KO (n=16) 
ALAT (µkat/l) 0.46 ± 0.15 below detection 0.5 ± 0.14 0.37 ± 0.04 
ALBUMIN (g/l) 29.46 ± 3.17 27.77 ± 5.67 33.07 ± 4.66 34.05 ± 2.96 
ALCALINE PHOSPHATASE (µkat/l) 0.6 ± 0.06 0.59 ± 0.12 0.84 ± 0.16 0.77 ± 0.17 
ASAT (µkat/l) 6.01 ± 3.77 1.88 ± 1.88** 1.53 ± 0.38 1.6 ± 0.41 
CALCIUM (mmol/l) 2.11 ± 0.17 2.13 ± 0.15 2.42 ± 0.23 2.42 ± 0.15 
CHOLINESTERASE (µkat/l) 81.77 ± 10.97 82.73 ± 11.05 120.64 ± 13.47 122.88 ± 13.11 
CHOLESTEROL (mmol/l) 2.71 ± 0.32 2.59 ± 0.49 2.71 ± 0.36 2.66 ± 0.53 
GLDH (µkat/l) 0.27 ± 0.25 0.16 ± 0.04 0.3 ± 0.11 0.23 ± 0.08 
UREA (mmol/l) 6.97 ± 1.26 8.8 ± 1.51** 4.32 ± 1.03 3.4 ± 0.60** 
LIPASE (µkat/l) 0.68 ± 0.21 0.49 ± 0.16* 0.47 ± 0.14 0.46 ± 0.11 
MAGNESIUM (mmol/l) 0.96 ± 0.18 1.12 ± 0.13* 1.29 ± 0.24 1.24 ± 0.23 
PROTEIN (g/l) 49.23 ± 3.73 47.7 ± 3.63 53.28 ± 6.03 54.03 ± 3.14 
PHOSPHATE (mmol/l) 2.05 ± 0.37 2.15 ± 0.33 1.91 ± 0.47 1.84 ± 0.24 
TRIGLYCERIDES (mmol/l) 0.71 ± 0.25 0.87 ± 0.32 0.97 ± 0.3 0.86 ± 0.22 
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 western diet male female 
WT (n=15) KO (n=15) WT (n=13) KO (n=13) 
ALAT (µkat/l) 0.67 ± 0.36 0.53 ± 0.18 0.42 ± 0.08 0.35 ± 0.03 
ALBUMIN (g/l) 23.89 ± 3.05 23.97 ± 4.2 30.83 ± 3 30.31 ± 3.41 
ALCALINE PHOSPHATASE (µkat/l) 0.57 ± 0.13 0.62 ± 0.11 0.78 ± 0.24 0.63 ± 0.12 
ASAT (µkat/l) 6.12 ± 3.5 6.37 ± 4.33 1.94 ± 0.27 2.16 ± 0.54 
CALCIUM (mmol/l) 1.9 ± 0.19 1.83 ± 0.24 2.51 ± 0.27 2.58 ± 0.2 
CHOLINESTERASE (µkat/l) 89.44 ± 11.23 86.45 ± 21.08 154.12 ± 12.47 152.62 ± 17.96 
CHOLESTEROL (mmol/l) 3.99 ± 0.55 4.13 ± 0.86 4.49 ± 0.47 4.3 ± 0.44 
GLDH (µkat/l) 1.18 ± 0.73 0.35 ± 0.20*** 0.89 ± 0.7 0.37 ± 0.12* 
UREA (mmol/l) 5.6 ± 1.81 6 ± 2.17 4.53 ± 0.71 5.32 ± 1.18 
LIPASE (µkat/l) 0.62 ± 0.31 0.99 ± 0.96 0.56 ± 0.19 0.59 ± 0.37 
MAGNESIUM (mmol/l) 1.05 ± 0.2 1.01 ± 0.09 1.3 ± 0.23 1.19 ± 0.28 
PROTEIN (g/l) 47.23 ± 4.35 46.64 ± 4.26 58.46 ± 3.42 57.63 ± 3.49 
PHOSPHATE (mmol/l) 2.19 ± 0.36 2.27 ± 0.27 2.67 ± 0.56 2.51 ± 0.38 
TRIGLYCERIDES (mmol/l) 0.97 ± 0.34 1.22 ± 0.58 0.94 ± 0.16 1.03 ± 0.59 
lipid profile after western diet male female 
WT (n=15) KO (n=15) WT (n=14) KO (n=12) 
HDL cholesterol (mmol/l) 4.49 ± 0.5 4.52 ± 0.99 3.13 ± 0.54 3.23 ± 0.52 
HDL triacylglycerides (mmol/l) 0.76 ± 0.07 0.75 ± 0.1 0.31 ± 0.05 0.38 ± 0.14 
LDL cholesterol (mmol/l) 1.86 ± 0.22 1.76 ± 0.31 1.87 ± 0.3 1.58 ± 0.17** 
LDL triacylglycerides (mmol/l) 1.46 ± 0.29 1.32 ± 0.19 0.55 ± 0.1 0.49 ± 0.11 
VLDL cholesterol (mmol/l) 0.22 ± 0.05 0.23 ± 0.04 0.31 ± 0.08 0.28 ± 0.09 
VLDL triacylglycerides (mmol/l) 1.16 ± 0.31 1.25 ± 0.29 0.44 ± 0.13 0.37 ± 0.12 
total cholesterol (mmol/l) 6.57 ± 0.72 6.52 ± 1.3 5.31 ± 0.79 5.09 ± 0.62 
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4.2 P2Y14 expression in mouse tissues 
Because the primary inspection did not reveal any prominent differences between WT and 
KO mice I next took advantage of the introduced LacZ reporter construct and monitored ß-
galactosidase activity in P2Y14-deficient mouse tissues to examine the P2Y14 expression at 
the cellular level. Whereas WT control tissues showed no specific staining, ß-galactosidase-
positive staining was found in uterus, bronchioles, blood vessels, pancreas, salivary glands 
(Fig. 3), and immune cells.  
Figure 3 Detection of bacterial 
LacZ reporter gene via ß-
galactosidase activity in 
cryosections of selected organs. 
To monitor the expression of P2Y14 
in vivo at the cellular level a 
transgenic KO mouse was generated 
by replacement of the P2Y14–coding 
region with an expression cassette 
harboring an internal ribosome entry 
site and the bacterial LacZ reporter 
gene under control of the 
endogenous P2Y14 promoter. Sites of 
LacZ expression were located in 
cryosections using X-Gal, and 
counterstained with nuclear fast red. 
Whereas no ß-galactosidase activity 
was detected in WT mice, KO mice 
showed intensive ß-galactosidase 
staining in several smooth muscle or 
contractile cell-containing organs. A 
indicates arterial vessel, V indicates 
venous blood vessel. 
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Interestingly, staining in the GI tract was positive only in a subpopulation of smooth muscle 
cells (Fig. 4A/B). In all parts of the GI tract smooth muscle cells of the thin layer of the 
muscularis mucosae were ß-galactosidase positive (Fig. 4A/B). From the ileum to the rectum 
a subpopulation of smooth muscle cells within the circular smooth muscle layer showed 
positive staining (Fig. 4A/B). In the rectum also the longitudinal smooth muscle layer 
displayed intensive ß-galactosidase activity (Fig. 4A/B). 
Co-staining of c-kit, which is a marker of Cajal cells and mast cells in the GI tract (60,61), 
revealed no obvious overlap with the ß-galactosidase-positive structures (data not shown). In 
contrast the ß-galactosidase staining was partly reminiscent of the reported divergent 
reactivity of intestinal smooth muscle cells with characteristic smooth muscle cell markers 
(i.e. alpha-smooth muscle actin (ASMA), gamma-smooth muscle actin (GSMA)) (62). 
Interestingly, cells next to the pancreatic acini (Fig. 5A-C) and myoepithelial cells of the 
salivary glands (Fig. 3) were stained. Further, few cells within the islet (Fig. 5 B/D) were ß-
galactosidase-positive. However, the distribution pattern of these cells did not completely 
correspond with one of the known major cell types within the islet of Langerhans.  
Figure 4 P2Y14 is expressed in a subpopulation of smooth muscle cells in the gastrointestinal 
tract. 
Expression of P2Y14 was monitored in vivo using a LacZ reporter gene (see 3.3.3). (A) KO mice 
showed intensive ß-galactosidase staining in a subpopulation of smooth muscle cells throughout the 
GI tract. (B) The expression of P2Y14 in certain muscle layers of the GI tract is schematically given. 
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Figure 5 Detection of bacterial LacZ reporter gene in cryosections of pancreas. 
(A/B) Expression of LacZ reporter gene in exocrine and endocrine parts of the pancreas. The 
enlarged picture details show the expression in the acini (B/C) and in cells of the islet (D).  
One should keep in mind that P2Y14 promoter-driven ß-galactosidase-expression was 
monitored in KO mice and may reflect transcript over- or even non-physiological expression 
due to P2Y14 deficiency. To address this issue, expression of the 5’UTR region of WT and 
KO P2Y14 gene transcripts, which were structurally similar in both WT and KO animals, was 
measured by qPCR in a number of tissues (Fig. 6). As presented in Fig. 6B, ΔCt values of 
transcript expression showed a high correlation between WT and KO in all tissues (r2 = 
0.9058). 
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Figure 6 P2Y14 transcript and P2Y14-promoter-driven LacZ gene expression in mouse tissues. 
Total RNA was extracted from several tissues from WT and P2Y14-KO mice (n=3) and mRNA levels 
of either P2Y14 or LacZ transcripts were determined by SYBR Green qPCR analysis. Expression data 
are shown as ΔCt values normalized to the house keeping gene ß2-microglobulin. (A) qPCR analysis 
shows a widespread receptor distribution with high expression levels in pancreas, salivary glands, 
brain and parts of the GI tract and lowest expression in liver. Data shown as mean ± SEM. (B) 
Expression of bacterial LacZ reporter gene in KO mice correlates (r2=0.9058) with the expression of 
P2Y14 in WT mice. Dashed line indicates the 95% confidence interval. 
Both data sets revealed that P2Y14 is widely expressed in mouse tissues with high expression 
levels in pancreas, salivary glands, brain, lung and parts of the gastrointestinal tract and 
lowest expression in liver (Fig. 6). 
4.3 Characterization of P2Y14 function in smooth muscles 
4.3.1 Delayed GI passage in P2Y14-deficient mice 
To study the consequences of P2Y14 deficiency in the GI tract, different segments of the 
intestine were placed in an organ bath and the contractile activity was recorded. Duodenal 
segments and segments of ileum and colon displayed regular basal activity showing no 
differences regarding mean muscle tension, amplitude or frequency of contractions between 
the genotypes. Following carbachol and electric stimulation all intestine segments of WT and 
KO mice showed an increase of contractile activity in a similar manner. Because no effect of 
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UDP-glucose (up to 1 mM) on basal and carbachol-stimulated and electric-stimulated 
contraction of isolated small intestine and colon was found (data not shown), I speculated that 
the contribution of P2Y14 is more distinct and may present its significance only when the 
entire GI passage is observed. Therefore, a dye-labeled dextran was applied to mice orally and 
the excretion in faeces was measured hourly. On average three hours after the oral application 
of dextran blue the mice begun to excrete the dye. In comparison to WT animals the expulsion 
of dextran blue was significantly delayed in KO mice (Fig. 7). Interestingly, more KO animals 
(5 KO vs. 1 WT) had to be excluded from analysis according to the exclusion criterion (see 
3.4.1). 
Figure 7 P2Y14-deficient mice showed a delayed gastrointestinal emptying. 
A dye-labeled dextran was applied to mice orally and the excretion in faeces was measured hourly. 
The excretion of blue dextran is shown relative to the total excreted blue dextran after 8 hours. Five 
KO mice but only one WT animal had to be excluded from analysis according to the exclusion 
criterion (see 3.4.1). OD620 nm (∆ 8h) = 0.8770 ± 0.0630 for WT and OD620 nm (∆ 8h) = 0.5636 ± 0.0731 for 
KO mice were set to 100%, respectively. Data shown as mean ± SEM. * P < 0.05; ** P < 0.01; *** P 
< 0.001; Student’s t-test 
4.3.2 Altered airway responsiveness in P2Y14-deficient mice 
P2Y14-reporter gene expression was also found in smooth muscle cells of bronchioles (Fig. 
3). To dissect P2Y14 function in respiratory tract invasive plethysmography experiments were 
performed testing airway resistance and dynamic compliance in intubated and mechanically 
ventilated mice. Aerosolized UDP-glucose had no effect on respiratory functions tested (Fig. 
8). Both WT and KO mice displayed adequate response to the cholinergic agent methacholine 
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(Fig. 8A). However, KO mice showed significantly higher dynamic compliance in response to 
increasing inhaled doses of methacholine (Fig. 8B). 
Figure 8 Airway responsiveness is reduced in P2Y14-deficient mice. 
Lung resistance (A) and dynamic compliance (B) were measured by invasive plethysmography 
(emka TECHNOLOGIES) in response to inhaled UDP-glucose and increasing doses of 
methacholine. Data shown as mean ± SD. Baseline values (set to 100%) were: lung resistance 1.28 ± 
0.41 mmHg x s/ml for WT mice and 1.11 ± 0.34 mmHg x s/ml for KO mice, dynamic compliance 
0.84 ± 0.56 ml/mmHg for WT and 0.72 ± 0.43 ml/mmHg for KO mice; * P < 0.05; Student’s t-test. 
For statistic analysis of the entire methacholine test a paired two-tailed t-test (marked by a long line) 
was performed (P = 0.0105 for dynamic compliance). 
4.4 P2Y14 deficiency alters metabolic functions 
4.4.1 P2Y14 deficiency results in reduced glucose tolerance 
The initial phenotype screen also included basic metabolic tests. Following oral glucose 
application KO mice showed significantly higher transient blood glucose levels (Fig. 9A). To 
differentiate whether the enteral glucose resorption was increased in KO mice due to the 
prolonged gastrointestinal emptying (see Fig. 7), intraperitoneal glucose tolerance tests were 
performed. Blood glucose levels were also increased in KO mice following intraperitoneal 
glucose injection (Fig. 9B) excluding differences in enteral glucose resorption. In order to 
evaluate the insulin sensitivity in KO mice insulin tolerance tests were performed. Both 
genotypes showed no alterations in the decline of blood glucose levels following 
intraperitoneal insulin injection (Fig. 10A), suggesting unchanged insulin sensitivity in KO 
mice. Serum insulin levels were analyzed during intraperitoneal glucose tolerance tests. Here, 
KO mice tended to have lower serum insulin levels after intraperitoneal glucose application 
(Fig. 10C). 
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4.4.2 Challenging the metabolic phenotype with a western type diet 
To study whether high caloric nutrition can aggravate the phenotype found in KO mice, 4-
week-old mice were kept on a western type diet for 3 months. WT and KO mice gained 
significantly body weight under the western type diet. But whereas there were no alterations 
in body weight development between WT and KO mice kept on standard diet, KO mice fed 
the western diet gained significantly less weight (KO: 178 ± 15% vs. WT: 196 ± 23%, P < 
0.05). However, detailed analysis of serum cholesterol and TAG levels in all lipoprotein 
fractions revealed no differences between WT and KO mice fed a western type diet (see 4.1 
Table 5). Interestingly, glucose tolerances following oral and intraperitoneal glucose 
application were significantly reduced in KO mice kept under western type diet (Fig. 9C/D). 
Next, insulin tolerance tests were performed to evaluate whether the higher glucose levels 
observed in KO mice in the oGTT were because of altered insulin sensitivity. There were no 
differences in the decline of blood glucose levels following intraperitoneal insulin injection 
Figure 9 P2Y14-deficient mice showed reduced glucose tolerance. 
Glucose tolerance tests were performed either by oral application (A, C) of 80 mg glucose or by 
intraperitoneal (B, D) glucose injection (2 mg/g body weight) to overnight fasted male mice kept 
under standard (A, B) or western (C, D) type diet. Blood glucose levels shown as mean ± SD. * P 
< 0.05; ** P < 0.01; *** P < 0.001; Student’s t-test 
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between WT and KO mice kept on western type diet (Fig. 10B), although both genotypes 
showed lower insulin sensitivity as a result of higher body weight due to high caloric 
nutrition. As insulin sensitivity did not account for altered oGTT in KO mice serum insulin 
levels in WT and KO mice during intraperitoneal glucose tolerance tests were analyzed. 
Interestingly, after 12 weeks of western type diet glucose-stimulated insulin secretion of KO 
mice was significantly lower 40 and 60 min after intraperitoneal glucose injection compared 
to WT mice (Fig. 10D).  
Figure 10 P2Y14-deficient mice showed diet-dependent lower serum insulin levels after glucose 
administration. 
First, blood glucose levels were measured in an insulin tolerance test (ITT) after intraperitoneal 
injection of insulin (0.75 U/kg body weight) in male mice kept under standard (A) and western (B) 
type diet. Blood glucose levels before insulin application (set to 100%) were 4.9 ± 0.6 mmol/l for 
WT and 5.8 ± 1.0 mmol/l for KO mice fed with standard diet, and 5.6 ± 0.7 mmol/l for WT and 6.1 ± 
0.9 mmol/l for KO mice kept under western type diet. Data shown as mean ± SD. * P < 0.05; 
Student’s t-test.  
Then, serum insulin levels were determined before (0 min) and 20, 40 and 60 min after 
intraperitoneal glucose injection (2 mg/g of body weight) in male mice kept under standard (C) and 
western type (D) diet. Data shown as mean ± SEM. ** P < 0.01; Student’s t-test 
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4.5 Normal architecture of pancreatic islets 
As the highest expression of P2Y14 was noticed in pancreas (Figs. 5 and 6) and the 
functional data pointed towards a lower pancreatic insulin secretion after oral und 
intraperitoneal glucose administration, morphometric analyses in H&E and insulin 
immunohistochemistry stained pancreatic slices in P2Y14-KO mice were performed.  
Neither the number nor the size of the pancreatic islets differed between WT and KO mice 
(Fig. 11A/C). Also, the insulin immunopositive areas were similar in both genotypes, 
suggesting no gross morphological abnormalities in islet development (Fig. 11B/D). 
 
Figure 11 Normal architecture of pancreatic islets in P2Y14-deficient mice. 
(A) Representative H&E stained pancreatic section used for morphometric analyses. (B) Insulin 
immunohistochemistry of representative pancreatic islets. (C) The number and area of islets in 10 
serial slices of pancreatic tissue were determined using NIH ImageJ Software. The number of islets 
was 141 ± 17 in WT and 157 ± 11 in KO mice. (D) β-cell mass was determined as ratio of insulin 
positive area to total pancreatic islet area. Data shown as mean ± SD.  
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4.6 Components involved in insulin release are differentially expressed in P2Y14-
deficient islets  
Since P2Y14-deficient islets did not show obvious morphological differences I screened for 
those at a molecular level. Thus, mRNA expression in isolated pancreatic islets from WT and 
KO mice was analyzed in a transcriptome-wide approach using RNA-sequencing. 
Approximately 13 million reads per animal were analyzed. The quality of the expression data 
was confirmed by verifying the presence of selected islet-specific transcripts. As expected, 
insulin, glucagon, somatostatin and SUR1/Kir6.2 transcripts were highly expressed in islets of 
both, WT and KO mice (Table 6).  
In line with the data from immunohistochemistry there was no difference in insulin mRNA 
expression levels between WT and KO (Table 6). The expression of P2Y14 gene was 
significantly reduced in KO mice (Table 6), but one should note that P2Y14 transcripts in the 
KO islets represented mRNA sequences of the 5’UTR region and not of the coding region 
(see Fig. 2). 
815 genes were found differentially expressed between WT and KO mice (329 transcripts 
downregulated, 486 transcripts upregulated, P < 0.05). Functional enrichment analysis of 
differentially expressed genes disclosed several GO (Gene Ontology) categories related to 
protein synthesis, signaling pathways and hormone secretion (Table 7).  
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 Table 6 Expression of selected transcripts related to insulin release in P2Y14-deficient and WT mice. 
Analysis of differential expression in pancreatic islets was performed using DESeq software package. 
Gene Name Ensembl ID Mouse Description normalized counts (DESeq) WT 
normalized counts (DESeq) 
KO p-value 
P2yr14 ENSMUSG00000036381 UDP-glucose receptor 150.669 ± 67.367 51.233 ± 31.351 1.55E-05 
Ins1 ENSMUSG00000035804 Insulin 1 1152011.035 ± 292272.566 1259275.220 ± 367446.561 0.39634 
Ins2 ENSMUSG00000000215 Insulin 2 23707662.257 ± 6243962.404 26673072.360 ± 7544683.224 0.32514 
Gcg ENSMUSG00000000394 Glucagon 1573442.614 ± 332358.640 1118086.770 ± 428209.260 0.00935 
Sst ENSMUSG00000004366 Somatostatin 109603.517 ± 26948.775 78143.829 ± 26039.779 0.03064 
Insr ENSMUSG00000005534 Insulin receptor 787.091 ± 93.101 918.837 ± 249.758 0.25710 
Insrr ENSMUSG00000005640 Insulin receptor-related receptor 15144.613 ± 3513.097 16533.489 ± 3935.146 0.55844 
Gcgr ENSMUSG00000025127 Glucagon receptor 1664.742 ± 428.258 1519.357 ± 316.953 0.48272 
Sstr1 ENSMUSG00000035431 Somatostatin receptor 1 42.117 ± 32.920 15.753 ± 9.191 0.03221 
Sstr2 ENSMUSG00000047904 Somatostatin receptor 2 184.474 ± 79.801 117.072 ± 66.365 0.02693 
Sstr3 ENSMUSG00000044933 Somatostatin receptor 3 2081.031 ± 553.613 2084.433 ± 394.202 0.92098 
Sstr4 ENSMUSG00000037014 Somatostatin receptor 4 3.725 ± 4.102 1.836 ± 3.349 0.83452 
Sstr5 ENSMUSG00000050824 Somatostatin receptor 5 1.714 ± 3.783 0.841 ± 1.995 1 
Slc2a2 ENSMUSG00000027690 GLUT2 13545.200 ± 4388.043 9864.047 ± 2396.638 0.02151 
Gck ENSMUSG00000041798 Glucokinase 5233.313 ± 2382.235 4290.637 ± 1140.332 0.47089 
Abcc8 ENSMUSG00000040136 SUR1 35996.663 ± 7296.922 33147.884 ± 7820.323 0.65933 
Kcnj11 ENSMUSG00000070561 Kir6.2 1395.498 ± 181.626 1448.442 ± 401.472 0.87691 
Pdx1 ENSMUSG00000029644 pancreatic and 1375.043 ± 385.507 1145.584 ± 120.464 0.16201 
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 duodenal 
homeobox 1 
Cacna1c ENSMUSG00000051331 
L-type calcium 
channel α1-
subunits 
4416.180 ± 1642.112 3020.178 ± 1114.107 0.03284 
Cacna1d ENSMUSG00000015968 6319.115 ± 1502.032 6014.105 ± 1966.976 0.54487 
Cacna1f ENSMUSG00000031142 126.956 ± 106.971 85.304 ± 35.759 0.36549 
Cacna1s ENSMUSG00000026407 2.895 ± 6.173 5.758 ± 12.204 0.19040 
Cacna1g ENSMUSG00000020866 T-type calcium 
channel α1-
subunits 
942.481 ± 437.464 772.241 ± 262.283 0.42725 
Cacna1h ENSMUSG00000024112 978.104 ± 393.856 615.766 ± 174.645 0.04259 
Cacna1i ENSMUSG00000022416 91.118 ± 64.381 65.418 ± 41.993 0.32531 
Cacna2d1 ENSMUSG00000040118 Voltage- 
dependent 
calcium channel 
α2δ-subunits 
10097.878 ± 2300.350 9583.156 ± 2186.810 0.54478 
Cacna2d2 ENSMUSG00000010066 711.329 ± 348.331 586.156 ± 217.327 0.41999 
Cacna2d3 ENSMUSG00000021991 126.052 ± 22.894 89.065 ± 31.253 0.07272 
Cacna2d4 ENSMUSG00000041460 30.534 ± 13.830 32.242 ± 32.546 0.50999 
Cacnb1 ENSMUSG00000020882 Voltage- 
dependent 
calcium channel 
β-subunits 
1236.722 ± 312.148 1214.727 ± 354.465 0.63333 
Cacnb2 ENSMUSG00000057914 1900.381 ± 463.540 1567.767 ± 289.201 0.14638 
Cacnb3 ENSMUSG00000003352 2214.024 ± 387.968 2105.138 ± 420.606 0.62697 
Cacnb4 ENSMUSG00000017412 112.675 ± 41.338 116.486 ± 37.496 0.53251 
Cacng1 ENSMUSG00000020722 
Voltage-
dependent 
calcium channel 
γ-subunits 
0 ± 0 0.171 ± 0.541 0.75784 
Cacng2 ENSMUSG00000019146 7.166 ± 5.535 3.537 ± 2.860 0.27770 
Cacng3 ENSMUSG00000066189 0.978 ± 2.122 3.992 ± 4.077 0.09313 
Cacng4 ENSMUSG00000020723 102.566 ± 48.997 111.682 ± 58.461 0.57746 
Cacng5 ENSMUSG00000040373 1.717 ± 3.288 1.543 ± 2.674 0.88201 
Cacng6 ENSMUSG00000078815 1.238 ± 3.915 1.699 ± 2.654 0.91835 
Cacng7 ENSMUSG00000069806 17.747 ± 13.035 22.773 ± 19.587 0.56912 
Cacng8 ENSMUSG00000053395 0.373 ± 1.179 0 ± 0 0.68948 
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Table 7 Functional enrichment analysis of differentially expressed genes in P2Y14-deficient compared to WT mice. 
  Genes   
ID Biological Process (downregulated in KO) (upregulated in KO) p-value 
GO:0003735 
structural 
constituent  
of ribosome 
  
Rps8, Rps12, Mrpl12, Rps3, Rpl36a, Rplp0, 
Rpl22, Rps27a, Rps15a, Rps27l, Mrpl11, 
Mrpl20, Mrps23, Mrpl15, Rpl6, Rpl11, Rpl12, 
Rpl17, Mrpl13, Mrpl33, Mrpl24 
0.0000104 
GO:0042886 amide transport 
Adora1, Slc2a2, Glp1r, Gal, Gcg, Cacna1c, 
Ffar1, Pde1c, Sc14a2, Rbp4, Itpr1, Mafa, 
Edn3, Ghrl, Stxbp5l,Gpr119, Cartpt 
Fam132a, Rasl10b, Bad, Ltbp4, Hla-drb1, 
Upk3a, Phpt1  0.0056743 
GO:0002790 peptide secretion 
Adora1, Slc2a2, Glp1r, Gal, Gcg, Cacna1c, 
Ffar1, Pde1c, Rbp4, Itpr1, Mafa, Edn3, Ghrl, 
Stxbp5l, Gpr119, Cartpt 
Fam132a, Rasl10b, Bad, Ltbp4, Hla-drb1, Phpt1  0.0092096 
GO:0006415 translational termination   
Rps8, Rps12, Rps3, Rpl36a, Rpl0, Rpl22, 
Rps271, Rps15a, Ict1, Rpl6, Rpl11, Rpl12, 
Rpl17  
0.0079669 
GO:0043624 
cellular protein 
complex  
disassembly 
Nes, Mical2 
Rps8, Rps12, Rps3, Stmn2, Rpl36a, Rpl0, 
Rpl22, Rps27a, Rps15a, Capza1, Ict1, Rpl6, 
Rpl11, Rpl12, Rpl17 
0.0121003 
GO:0007218 
neuropeptide 
signaling  
pathway 
Gpr115, Glp1r, Gal, Calca, Sstr1, Sstr2, 
Gpr111, Gpr112, Gpr98, Cartpt, Lphn3 Nmur1, Galr1, Hcrtr2, Emr1 0.0123548 
GO:0043241 protein complex disassembly Nes, Mical2 
Rps8, Rps12, Rps3, Stmn2, Rpl36a, Rpl0, 
Rpl22, Rps27a, Rps15a, Capza1, Ict1, Rpl6, 
Rpl11, Rpl12, Rpl17 
0.0186688 
GO:0030072 peptide hormone secretion 
Slc2a2, Glp1r, Gal, Gcg, Cacna1c, Ffar1, 
Pde1c, Rbp4, Itpt1, Mafa, Edn3, Ghrl, Stxbp5l, 
Gpr119, Cartpt 
Fam132a, Rasl10b, Bad, Ltbp4, Hla-drb1, Phpt1,  0.02243 
GO:0015833 peptide transport 
Adora1, Scl2a2, Glp1r, Gal, Gcg, Cacna1c, 
Ffar1, Pde1c, Rbp4, Itpr1, Mafa, Edn3, Ghrl, 
Stxbp5l, Gpr119, Cartpt 
Fam132a, Rasl10b, Bad, Ltbp4, Hla-drb1, Phpt1 0.0321108 
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GO:0010817 regulation of hormone levels 
Adh4, Adh1, Adora1, Cacna1h, Slc2a2, Glp1r, 
Gal, Gcg, Cacna1c, Ffar1, Hsdrb2, Pde1c, 
Rbp4, Itp r1, Mafa, Edn3, Ghrl, Stxbp5l, 
Gpr119, Cartpt, Enpep 
Fam132a, Rasl10b, Bad, Ltbp4, Tg, Ngf, 
Sult1e1, Hla-drb1, Lrat, Phpt1, Reln 0.0548341 
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Since serum insulin levels were reduced in KO mice I mainly focused on genes known to be 
related to glucose sensing, insulin exocytosis and its modulation. Selected components 
involved in insulin release and their changes in transcript levels are schematically given in 
Figure 12. 
 
Figure 12 Signaling pathways involved in insulin secretion from β-cells.  
Several components involved in insulin release from pancreatic islets are shown. P2Y14 deficiency 
led to increased (green) and decreased (red) transcription of several genes compared to islets from 
WT mice. Detailed data from RNASeq experiments are given in Table 6 and Table 7. 
Glucose uptake through the glucose transporter 2 (GLUT2) is a first key step in regulation of 
insulin release (63) (Fig. 12). The expression of GLUT2 (Slc2a2) was significantly 
downregulated in KO.  
The major trigger of insulin vesicle exocytosis is an increase in intracellular Ca2+ (63) and 
cAMP and protein kinase A (PKA) activity are known to amplify insulin exocytosis (64). In 
the classical model of GPCR-modulated insulin release, Gq (Ca2+) and Gs (cAMP) activating 
receptors promote insulin release, whereas Gi/o protein-coupled receptors reduce insulin 
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release by inhibiting adenylyl cyclases and reducing cAMP levels in β-cells. Indeed, several 
components involved in receptor- and ion channel-controlled intracellular Ca2+ levels were 
downregulated in islets of KO mice, among them the subunits CACNA1C and CACNA1H of 
the voltage-dependent Ca2+ channels (VDCC), the endoplasmic reticulum IP3 receptor 
(ITPR1), cAMP-degrading phosphodiesterases PDE1C and PDE4D (65), several GPCR 
known to modulate insulin release such as the free-fatty acid receptor FFAR1 (66), calcium-
sensing receptor (CASR), GLP1 receptor (GLP1R), GPR119, somatostatin receptors SSTR1 
and SSTR2 (and their agonist somatostatin) (46,67). 
4.7 Reduced insulin release from pancreatic islets of P2Y14-deficient mice 
It is almost impossible to functionally analyze all components found to be differentially 
expressed between WT und KO at both, their individual level and their signaling network 
level. Therefore, I studied insulin secretion, as one integral islet function, in perifused and 
static treated islets in vitro. 
Although intracellular insulin content was similar in lysed islets isolated from WT and KO 
mice (Fig. 13A), the insulin release following stimulation with low (2.8 mM) and high 
glucose (16.7 mM) during a 30 min incubation was significantly reduced in islets lacking 
P2Y14 (Fig. 13B/C). To study the kinetics of insulin release, isolated islets were placed in a 
perifusion chamber and continuously perifused with KRB solution containing different 
glucose concentrations. The initial insulin release peak and the sustained insulin release were 
significantly reduced in KO islets stimulated with a high glucose concentration (16.7 mM) 
(Fig. 13D). Stimulation of the isolated pancreatic islets with UDP-glucose alone and in 
presence of 16.7 mM glucose did not significantly reduce or increase insulin release (Fig. 
13B-D). 
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Figure 13 Impaired insulin secretion of isolated pancreatic islets of P2Y14-deficient mice. 
For cumulative insulin measurements (A-C), pancreatic islets were isolated from WT and KO male 
mice and incubated 30 min with KRB solution containing 2.8 mM glucose, 16.7 mM glucose or 16.7 
mM glucose plus 100 µM UDP-glucose (n=5-7). Insulin levels of lysed islets (A), in the supernatants 
(B) and the ratio of both (C) are shown. For kinetic insulin measurements (D), pancreatic islets were 
isolated from WT and KO male mice and continuously perifused with KRB solution containing 2.8 
mM glucose, 16.7 mM glucose, or 16.7 mM glucose plus 100 µM UDP-glucose. Insulin levels 
shown as mean ± SEM. * P < 0.05; ** P < 0.01; *** P < 0.001; Student’s t-test 
4.8 Functional characterization of mouse and human P2Y14 
Because UDP-glucose showed no physiological activity on WT mouse tissues in several 
assays (see 4.3.1, 4.3.2, 4.7), the agonistic properties of UDP and UDP-glucose were 
reevaluated using several different in vitro approaches.  
First, a heterologous yeast expression system was used because it lacks any nucleotide 
receptors. Here, GPCR activation is linked to cell growth via a chimeric G protein. The mouse 
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ADP receptor P2Y12 served as positive control and showed a robust cell growth upon MeS-
ADP stimulation whereas UDP and UDP-glucose had no effect on P2Y12 (Fig. 14). When 
expressed in this yeast cell system the mouse P2Y14 displayed a high constitutive activity 
compared to P2Y12 (Fig. 14A). Both, UDP-glucose and UDP, were able to slightly increase 
yeast growth (Fig. 14A) suggesting some agonistic activity at P2Y14.  
Since results from this artificial system are not always transferable to mammalian cell 
expression systems (68) the mouse and the human P2Y14 cotransfected with a chimeric Gαsi5 
protein were tested in mammalian cells using direct cAMP measurements. This chimeric G 
protein directs Gi-coupled receptors to the Gs/adenylyl cyclase pathway. Mock transfected 
cells were used as negative control. The positive controls (mouse Y2 and human muscarinic 
M2 receptors) displayed adequate response to their agonists neuropeptide Y (NPY) and 
carbachol (Cch), respectively (Table 8). The human and mouse P2Y14 showed increased basal 
activity but only an insignificant increase of cAMP levels (Table 8) upon stimulation with 
UDP or UDP-glucose. 
Table 8 Functional measurements of mouse and human P2Y14 receptors. 
Mouse and human P2Y14 constructs and two other Gi-coupled receptors as controls were transfected 
for cAMP inhibition and direct cAMP measurements (via a chimeric Gαsi5 protein) as described in 
3.8. For inhibition of cAMP, transfected COS-7 cells were stimulated either with 5 µM forskolin 
(FSK) or together with the indicated agonists for 15 minutes. Forskolin-stimulated values of each 
receptor were set 100% and % of inhibition due to the agonist stimulation was calculated for each 
receptor. Forskolin-stimulated cAMP values for each receptor and mock transfected cells (in nM) are 
given in brackets. Basal cAMP levels prior Forskolin-stimulation for mock-transfected cells were 
0.88 ± 0.57 nM. The number of assays is indicated in each column. All assays were performed in 
triplicates. 
  cAMP inhibition cAMP (nM) 
  
 % of FSK stimulation  cotransfected Gαsi5 
transfected construct agonist (n=10) (n=4) 
mock 
FSK/basal 100 (7.78 ± 1.29) 2.71 ± 1.42 
UDP 96.93 ± 9.53 2.95 ± 2.22 
UDP-Glc 104.06 ± 18.13 3.12 ± 1.18 
NPY 106.08 ± 27.75 3.12 ± 1.44 
CCh 92.13 ± 17.59 2.67 ± 1.76 
mouse P2y14 
FSK/basal 100 (8.96 ± 1.92) 7.22 ± 1.99 
UDP 103.37 ± 22.91 8.10 ± 2.18 
UDP-Glc 93.81 ± 21.66 9.20 ± 2.05 
human P2Y14 
FSK/basal 100 (8.73 ± 3.12) 7.49 ± 3.00 
UDP 99.10 ± 18.56 8.04 ± 3.26 
UDP-Glc 98.88 ± 21.47 8.86 ± 3.50 
mouse Y2R 
FSK/basal 100 (11.54 ± 3.21) 4.18 ± 0.98 
NPY 64.49 ± 15.09 12.10 ± 3.24 
human M2R 
FSK/basal 100 (12.09 ± 3.30) 4.93 ± 0.56 
CCh 80.00 ± 21.28 11.34 ± 2.96 
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Next, COS-7 cells transfected with the human and mouse P2Y14 were tested in classical 
cAMP inhibition assays where cAMP levels were increased by forskolin. In contrast to the 
experiments with chimeric G proteins no increased basal activity was seen in P2Y14-
transfected cells (Table 8). Neither UDP nor UDP-glucose showed agonistic activity at P2Y14 
whereas stimulation of Gi-coupled Y2 and muscarinic M2 receptors partially inhibited 
forskolin-induced cAMP formation (Table 8). 
Finally, the mouse P2Y14 was tested in a more sensitive and kinetic assay using dynamic 
mass redistribution (EPIC ®). Experiments showed no significant signal for UDP-glucose and 
UDP on mouse P2Y14-transfected compared to mock-transfected cells (Fig. 14B). However, 
the neuropeptide Y Y2 receptor (positive control) showed a robust transient after NPY 
stimulation (Fig. 14B). 
 
Figure 14 Testing UDP-glucose and UDP at P2Y14 in yeast and mammalian cells. 
(A) Genetically engineered yeast cells (69) transformed with the indicated receptor constructs were 
analyzed without (basal) and with agonist (10 µM). Receptor activation was measured after 40 hours 
as growth of yeast cells in histidine-depleted medium by recording the optical density (OD) at 600 
nm. Data (mean ± SD) from two independent experiments (in triplicate) are shown. (B) Transiently 
transfected HEK293 cells (P2Y14, neuropeptide Y receptor Y2) were seeded in 384-well plates the 
day prior DMR measurements (59). Cells were challenged with indicated concentrations of the 
corresponding agonist (UDP, UDP-glucose, NPY) and wavelength shift (in pm) was monitored. Each 
receptor stimulation curve was first corrected against own buffer control (basal) and second, against 
mock-transfected cells stimulated with the respective agonist. Data from three independent 
experiments (mean ± SEM) were summarized, each performed in quadruplicate. 
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5 DISCUSSION 
Although widely expressed, previous studies on P2Y14 mainly focused on immune cells 
and its relevance in inflammatory responses (13,32,34,35,40-42). Initial evidence indicates a 
role of P2Y14 in UDP-glucose-mediated chemotaxis of neutrophils and bone marrow cells, 
mast cell degranulation and proliferation of T cells (34,35,43,70). However, studies suggest 
that UDP-glucose can mediate cellular effects via P2Y14-dependent and -independent 
pathways (45,71,72). To study the physiological function of P2Y14 a KO mouse line was 
established by targeted deletion of this GPCR gene and replacement with a LacZ reporter 
gene.  
5.1 P2Y14 deficiency is compatible with life 
The P2Y14-deficient offspring was characterized in a primary screen searching for major 
anomalies in morphology and development. KO mice were vital and fertile. This is consistent 
with a very recent study investigating P2Y14 relevance in embryonic lethality after radiation 
(44). Except for a significantly higher spleen weight (Table 1) and slightly increased blood 
pressure (Table 2) no obvious differences in genotype distribution, breeding, growth, gross 
morphology, histology, laboratory chemistry and behavior were detected on primary 
inspection in comparison to WT mice (Tables 3-5). Scrivens and Dickenson (35) focused in 
their study on the expression of P2Y14 in spleen and characterized the involvement of this 
GPCR in T-cell function. Indeed, UDP-glucose was able to inhibit the proliferation of murine 
spleen-derived T-cells induced by IL-2 and anti-CD3 antibody treatment (35). In line with my 
data, Kook et al. (44) described higher spleen weights of P2Y14-deficient offspring following 
prenatal radiation, suggesting a protective effect of P2Y14 deficiency in preventing spleen cell 
damage. Controversially, in utero pretreatment of WT mice with the putative receptor agonist 
UDP-glucose mimicked the effect found in mice lacking P2Y14 (44). 
However, the rather mild phenotype of P2Y14-deficient animals was observed under SPF 
conditions. It was shown that over 40% of all GPCR-deficient mouse models only display an 
obvious phenotype after challenging with a pathogen, drug or other challenging conditions 
(47). Therefore, tissue distribution analyses are often useful to obtain information about 
possible functions. 
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5.2 P2Y14 is widely expressed in mouse tissues 
Quantitative PCR analyses showed a ubiquitous expression of P2Y14 in mouse tissues with 
high expression levels in pancreas, salivary glands, brain, lung and the GI tract and lowest 
expression in liver (Fig. 6A) Taking advantage of the introduced LacZ reporter construct the 
expression was tracked to a subpopulation of smooth muscle cells throughout the GI tract 
(Fig. 4). Several co-stainings with known smooth muscle cell markers revealed no overlap 
with the ß-galactosidase-positive cells. To my best knowledge, there is no other smooth 
muscle subtype which may correspond to the cells marked by the P2Y14-reporter construct 
and may indicate a previously non-described smooth muscle cell subpopulation. 
Reporter gene expression can, in principle, show adverse expression effects due to adaptation 
to the lack of the deleted gene. To address this issue P2Y14 and LacZ reporter gene expression 
were studied in WT and KO mice. Quantitative PCR experiments showed that the mRNA 
expression levels and the tissue expression specificity of the reporter LacZ was similar to 
P2Y14 (Fig. 6B). This equivalence of transcript levels almost excluded compensatory or 
reactive LacZ expression effects following P2Y14 deficiency in KO tissues and showed that 
the reporter gene properly indicates P2Y14 expression in tissues. Furthermore, it implicates 
that the reporter gene construct most probably does not influence the phenotypes that were 
studied in more detail. 
The ubiquitous expression of P2Y14 in mouse tissues is in accord with previous findings in 
human and rat tissues (32,39,40) but now adds that in many organs distinct smooth muscle 
cells are the cellular basis of broad expression levels previously found in qPCR and Western 
blot analyses. 
5.3 P2Y14 deficiency alters smooth muscle functions in GI tract and airways  
To study the consequences of P2Y14 deficiency in the different smooth muscle-containing 
organs several GI tract and bronchial tract functions were tested. A previous study in rat 
revealed high P2Y14 mRNA levels and found UDP-glucose-dependent increase in the 
baseline muscle tension of the forestomach. However, comparison of WT und P2Y14-
deficient mice revealed no differences in gastric emptying (45). 
In studies with isolated intestine the contractility of several GI segments of KO mice was not 
different from those of WT mice following electric and carbachol stimulations. Moreover, 
UDP-glucose showed no effect on contraction of intestine preparations of WT mice. 
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However, observing the entire GI passage the lack of P2Y14 reduced GI emptying (Fig. 7), 
suggesting a more distinct effect of P2Y14 on smooth muscle function of the GI tract. 
Interestingly, P2Y14-expressing bronchioles were also affected by deficiency of this GPCR. 
Thus, P2Y14-KO mice displayed a higher dynamic compliance in response to inhaled 
methacholine (Fig. 8) during invasive plethysmography tests. Taken together, with the 
previously described role of P2Y14 in immune and inflammatory responses this is an 
interesting finding as chronic pulmonary diseases like asthma or chronic obstructive 
pulmonary disease (COPD) show inflammatory and narrowing remodeling processes in the 
bronchioli and airway hyperresponsiveness (73,74). Indeed, it has been shown that sputum 
samples from patients with airway inflammation contain higher levels of UDP-glucose (75) 
and Müller et al. (76) described the involvement of P2Y14 in release of chemokines like IL-8 
from human airway epithelial cells. Interestingly, the involvement in asthma pathogenesis has 
been demonstrated for the ADP receptor P2Y12, another member of the P2Y12-like receptor 
group (77). 
By analogy, differential expression of P2Y14 was also found in intestinal biopsies of patients 
with chronic bowel diseases (78). This group of disorders comprises Crohn’s disease and 
ulcerative colitis and is characterized by intestinal inflammation (77). In fact, P2Y14 was the 
only nucleotide receptor-related gene that displayed a positive expression correlation with 
grade of inflammation in ulcerative colitis (78). Further studies of P2Y14 function in murine 
models of acute or chronic lung diseases and inflammatory bowel diseases are required to 
dissect its possible contribution to these disorders. 
Furthermore, one should note, that P2Y14 is expressed in venous blood vessels (Fig. 3) and 
P2Y14 deficiency led to significant increases in blood pressure and heart rate (Table 2). There 
is some evidence that P2Y14 may have vasocontractile function on arteries (79) but P2Y14 
expression in smooth muscle cells in arteries is controversially discussed (80,81). I found 
some ß-galactosidase positive arteries only in lung and CNS (circulus arteriosus Willisii) 
(data not shown). Future studies will address if there is a physiological link between P2Y14 
expression in the vascular system and hemodynamic functions. 
In sum, these studies show that P2Y14 is highly expressed in a distinct subset of smooth 
muscle cells. P2Y14 expressed on those cells modulate contractile function of the GI and the 
bronchial tracts. 
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5.4 P2Y14 deficiency results in reduced glucose tolerance  
The most obvious phenotype was the reduced oral glucose tolerance (Fig. 9A/C) in P2Y14-
deficient mice. Altered glucose resorption, reduced insulin sensitivity and decreased 
pancreatic insulin secretion can contribute to an impaired oral glucose tolerance. Resorptional 
problems in the GI tract could not account for the reduced oral glucose tolerance since P2Y14-
KO mice also showed significantly higher blood glucose levels following intraperitoneal 
glucose injection (Fig. 9B/D). The observed reduced glucose tolerance in P2Y14-deficient 
mice more likely results from the lower pancreatic insulin secretion after glucose application 
(Fig. 10C/D). In a recent paper, Xu et al. (82) showed improved glucose tolerance in P2Y14-
deficient mice fed with a high-fat diet due to an elevated insulin sensitivity e.g. of the liver. 
This is in contrast to my data where insulin sensitivity of KO and WT mice was not different 
(Fig. 10A/B). It was argued that reduced macrophage infiltration and hepatic inflammation 
account for improved hepatic insulin sensitivity (82). As in my study (Fig. 10C/D), Xu et al. 
(82) found reduced serum insulin levels after glucose administration in KO mice. This 
important finding remained unappreciated in their study and other pathophysiological 
mechanisms were not considered. In a more reasonable scenario, lower insulin levels result in 
a reduced hepatic steatosis, as found in (82) under high-fat diet. In fact, the differential 
expression of genes involved in lipid and glycogen metabolism in liver, as found in (82), can 
be interpreted as a consequence of lower insulin levels. It is well known that insulin 
stimulates the expression of lipogenic enzymes such as fatty-acid synthase and acetyl-CoA 
carboxylase and inhibits the transcription of gluconeogenic enzymes such as glucose-6-
phosphatase and phosphoenolpyruvate carboxykinase (83). The hepatic inflammation is most 
likely secondary to the alimentary hepatic steatosis found in Xu et al (82). Since the western 
type diet I used in my experiments does not significantly differ from the high-fat diet (see 3.5) 
Xu et al. fed the mice (26.3% carbohydrates, 34.9% fat, 26.2% protein) I further focused on 
the reason for the lower blood insulin levels (Fig. 10 C/D) which were seen already in animals 
fed with standard chow. 
5.5 Reduced insulin release from P2Y14-deficient islets 
Since morphological changes and altered number of pancreatic islets did not account for 
the reduced serum insulin levels in P2Y14-deficient mice, differences at the molecular level 
were studied in detail using a transcriptome-wide approach. 
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In line with ß-galacosidase staining of pancreatic tissue (Fig. 5D), the RNA-sequencing data 
(Table 6), also qPCR analysis (∆Ct = 7.64 ± 0.55), and other studies (46) clearly demonstrate 
P2Y14 expression in pancreatic islets. Transcriptome data showed significant changes in 
relevant components of glucose sensing, Ca2+-triggered and GPCR-modulated insulin release 
pathways (Fig. 12) in islets of P2Y14-deficient mice which suggested changes in islet function 
of KO animals and indeed, in vitro experiments revealed a negative impact of P2Y14 
deficiency on glucose-dependent insulin release from isolated pancreatic islets (Fig. 13) and 
confirmed my in vivo findings. 
Since P2Y14 couples to Gi/o proteins, inhibits adenylyl cyclases and mobilizes intracellular 
Ca2+ (41,43) most probably via release of Gβγ dimers from Gi proteins (84), one would expect 
that loss of this gene should rather improve glucose-mediated insulin release from β-cells. 
However, UDP-glucose alone was neither able to significantly release insulin nor 
significantly reduce glucose-induced insulin release from isolated islets (see Fig. 13B-D). 
Therefore, I re-evaluated the agonistic properties of UDP- and UDP-glucose at the mouse and 
human P2Y14 with different methods in vitro. Techniques using chimeric G proteins in yeast 
and mammalian heterologous expression systems showed high basal activity of P2Y14 and 
some minor UDP- and UDP-glucose-mediated responses (Fig. 14A, Table 8). However, UDP 
and UDP-glucose did not significantly activate P2Y14 in classic cAMP inhibition assay (Table 
8) and label-free DMR (Fig. 14B), whereas the Gi-coupled neuropeptide Y receptor Y2 
showed robust agonist-mediated signals in all tests. At the current stage, UDP and UDP-
glucose show weak agonistic activity at P2Y14 in functional assays using chimeric G proteins 
(30). Label-free and classic second messenger assays as well as my in vivo data with knock-
out mice do not provide evidence for physiological activities of UDP and UDP-glucose at 
P2Y14. Further studies using clear-cut controls (e.g. gene-deficient animals) are required to 
finally prove or disprove UDP-Glc and UDP as physiological agonists for P2Y14. 
The cell type within Langerhans islets, where a specific GPCR is expressed, determines its 
function on insulin exocytosis. Currently, the cell type(s) of pancreatic islets expressing 
P2Y14 is unknown. Further, the effect of a given GPCR on insulin release apparently not only 
depends on its G protein-coupling mode. Thus, Gq protein-coupled receptors such as the 
GnRH receptor inhibits insulin release whereas the exclusively Gi protein-coupled 
cannabinoid receptor type 1 and the melanin-concentrating hormone receptor stimulate insulin 
release from islets (46). The most abundant somatostatin receptor SSTR3 (see Table 6), which 
is Gi/o protein-coupled, has no significant effect on insulin release (46). As for several GPCR 
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expressed in pancreatic islets (46) the specific signaling pathway how P2Y14 modulates gene 
expression and functions of islets needs to be studied further. 
5.6 Conclusion 
Mice with P2Y14 deficiency present a rather mild phenotype under SPF conditions. 
However, my studies revealed involvement of P2Y14 in GI tract emptying and glucose 
homeostasis regulation. The lack of P2Y14 function reduced intestine passage and glucose-
stimulated insulin release from pancreatic islets in vitro and in vivo. It is of interest that 
several GPCR, e.g. GLP1R, GPR39, M3 muscarinic receptor and galanin receptor, modulate 
both, GI motility and glucose-induced insulin secretion (85-88). For P2Y14 it is currently 
unclear whether this GPCR realizes its effect by acute activation of its signaling cascade or 
during islet ontogenesis. The gross transcriptome changes found in P2Y14-deficient islets may 
also suggest a more complex alteration of the expression profile indicating a role of P2Y14 in 
subdifferentiation of islets cells. Indeed, some genes which are involved in differentiation and 
maturation of pancreatic islet cell types (e.g. MAFA, MAFB, REG2) (89-91) are differentially 
expressed in the islets isolated from P2Y14-deficient mice (Fig. 12). Although there were no 
differences in gross islet morphology and islet size distribution (Fig. 11), there is evidence 
that e.g. pancreatic β-cells are not homogenous but rather present functionally different 
subpopulations with distinguishable functionality (92,93). Thus, P2Y14-mediated signaling 
may be one signal that modulates distinct functionalities of islet cells. Since Langerhans islets 
derived from pancreatic ductal cells during ontogenesis and P2Y14 expression was 
morphologically also found in the exocrine pancreas (Fig. 5A-C), more detailed studies 
should focus on the relevance of P2Y14 in pancreas development. Further studies with 
conditional β-cell-specific KO mice can help to differentiate between acute and adaptive 
effects of P2Y14 deficiency. Moreover, P2Y14 gene variants may contribute to a prediabetic 
state that enhances the risk of metabolic disease in humans. This obviously raises the 
questions whether there are polymorphisms of the P2Y14 gene within the human population 
that define this risk and whether signatures of recent selection can be found at the locus. 
Nevertheless, findings in this study identify P2Y14 as a novel modulator of insulin secretion. 
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G protein-coupled receptors (GPCR) play a significant role in regulating virtual all 
physiological functions and more than one third of currently clinically used drugs target 
GPCR. However, there are approximately one hundred so-called orphan GPCR to whom 
neither the physiological function nor the endogenous ligand has been assigned yet. 
Therefore, the identification of their role in organism could display new targets for therapeutic 
applications.  
The UDP-glucose receptor P2Y14 is a GPCR that belongs to the family of the P2Y12-like 
receptors due to phylogenetic relation. This group comprises among other receptors the 
clopidogrel-sensitive ADP receptor P2Y12 whose pivotal role in platelet aggregation and 
immune function has been well characterized in several studies. However, only little is known 
about the physiological function of other GPCR of the P2Y12-like receptor group. Previous 
studies on P2Y14 function focused on its involvement in immune and inflammatory responses 
based on the high abundance of this GPCR in the immune system. Because high expression 
was found in the gastrointestinal (GI) system, it seemed reasonable to investigate a possible 
role of P2Y14 in the regulation of nutrient uptake and energy metabolism. Taking advantage 
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of a gene-deficient (KO) mouse strain this study aimed at the characterization of the 
biological consequences of UDP-glucose receptor deficiency. 
The study revealed the following main results: 
1. The generated P2Y14-KO mouse strain showed no obvious phenotypes regarding 
genotype distribution, breeding, growth, development and morphology. The 
P2Y14-deficient offspring was vital and fertile and displayed no gross differences 
in laboratory screens and behavioral tests except for a higher spleen weight and 
increased blood pressure and heart rate under specific pathogen free (SPF) 
conditions. 
2. P2Y14 is widely expressed in mouse tissues showing high expression levels in 
pancreas, salivary glands, brain, lung, and parts of the GI tract and lowest 
expression in liver. Using a LacZ reporter gene the expression of the P2Y14 was 
tracked to distinct smooth muscle cells within the GI tract. This smooth muscle 
cell population is different to any other described subpopulations (e.g. Cajal cells). 
3. P2Y14 deficiency in mice results in altered smooth muscle function in the GI and 
bronchial tracts. P2Y14-KO mice show a prolonged GI passage in GI transit 
experiments. In an invasive plethysmography test mice deficient for P2Y14 showed 
enhanced lung compliance following increasing doses of inhaled methacholine. 
These results indicate a role of P2Y14 in modulating the contractile function of 
smooth muscle cells expressing this GPCR. 
4. Metabolic studies revealed a reduced oral and intraperitoneal glucose tolerance in 
P2Y14-KO mice kept under standard and western type diet. By performing insulin 
tolerance and insulin secretion tests this phenotype was pinpointed to lower serum 
insulin levels following glucose application in mice lacking P2Y14. 
5. Morphometric analyses of pancreatic tissue displayed no differences in number 
and size of the islets of P2Y14-KO mice in comparison to WT mice, suggesting no 
gross morphological abnormalities in islet development. 
6. To assess possible differences in islets of P2Y14-KO mice at the molecular level 
RNA expression was analyzed in a transcriptome-wide approach using RNA-
sequencing. 815 genes were found differentially expressed between the islets of 
KO and WT mice. Transcriptome data show significant alterations in expression of 
components relevant for glucose sensing, Ca2+-triggered and GPCR-modulated 
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insulin release pathways in islets of P2Y14-deficient mice suggesting changes in 
islet function of KO animals. 
7. In vitro insulin secretion experiments demonstrated a reduced insulin release from 
isolated pancreatic islets of P2Y14-deficient mice despite similar amount of 
produced insulin in islets isolated from both WT and KO mice. 
In conclusion, mice with P2Y14 deficiency present a rather mild phenotype with higher spleen 
weight and delayed GI tract emptying under SPF conditions. However, more detailed analysis 
of metabolic parameters revealed a significantly reduced glucose tolerance and insulin 
secretion in KO mice. In addition to immune function these metabolic data indicate a role of 
P2Y14 in the regulation of energy homeostasis via modulation of the insulin release. 
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Background: The relevance of the widely 
expressed GPCR P2Y14 is only partially 
understood. 
Results: Analysis of P2Y14 KO mice revealed 
decreased gastrointestinal emptying, reduced 
glucose tolerance and insulin release. 
Conclusion: P2Y14 function is required for proper 
intestine emptying and adequate glucose response. 
Significance: P2Y14 plays a role in smooth muscle 
function and maintaining energy homoeostasis by 
influencing insulin release. 
 
ABSTRACT 
UDP-sugars were identified as extracellular 
signaling molecules, assigning a new function to 
these compounds in addition to their well 
defined role in intracellular substrate 
metabolism and storage. Previously regarded as 
an orphan receptor, the G protein-coupled 
receptor (GPCR) P2Y14 (GPR105) was found to 
bind extracellular UDP and UDP-sugars. Little 
is known about the physiological functions of 
this GPCR. To study its physiological role we 
used a gene-deficient (KO) mouse strain 
expressing the bacterial LacZ reporter gene to 
monitor the physiological expression pattern of 
P2Y14. We found that P2Y14 is mainly 
expressed in pancreas and salivary glands and 
in subpopulations of smooth muscle cells of the 
gastrointestinal tract, blood vessels, lung and 
uterus. Among other phenotypical differences 
KO mice showed a significantly impaired 
glucose tolerance following oral and 
intraperitoneal glucose application. An 
unchanged insulin tolerance suggested altered 
pancreatic islet function. Transcriptome 
analysis of pancreatic islets showed that P2Y14 
deficiency significantly changed expression of 
components involved in insulin secretion. 
Insulin secretion tests revealed a reduced 
insulin release from P2Y14-deficient islets 
highlighting P2Y14 as a new modulator of 
proper insulin secretion. 
 
Although the physiological function is known 
for many members of the family of GPCR, 
functional ligands have not been identified yet for 
more than one hundred so-called orphan receptors. 
In the past years, academic research groups and 
pharmaceutical companies engaged in large-scale 
deorphanization efforts for these receptors 
employing ligand screening studies and analyses of 
receptor-deficient mouse models (1). One of these 
studies revealed P2Y14 (formerly named GPR105) 
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as a receptor that is activated by UDP-glucose and 
closely related sugars (2,3). This was an interesting 
finding as UDP-glucose is a pivotal metabolite in 
intracellular glucose storage pathways including 
glycogen biosynthesis. In more recent studies, 
UDP alone was described as ligand for P2Y14 
(4,5), however, another group tested the agonistic 
activity of UDP but found no activation of P2Y14 
(2). P2Y14 belongs to the P2Y12–like receptor 
group within the family of rhodopsin-like 
receptors. The P2Y12–like receptor group 
comprises the ADP receptors P2Y12 and P2Y13, 
P2Y14 and the receptors GPR34, GPR82, GPR87, 
and GPR171 (6). P2Y14 mRNA expression 
analysis showed a widespread expression pattern 
including high expression levels in placenta, 
adipose tissue, stomach and intestine and moderate 
levels in spleen, lung, heart and different brain 
regions (3,7). P2Y14 was also detected in immune 
cells like B- and T-lymphocytes, neutrophils, 
dendritic cells, astrocytes, and microglia (7-11) 
suggesting a physiological function in immune 
response. Indeed, expression of P2Y14 was 
upregulated in response to inflammatory injury 
(12) and similar results were shown by in vivo 
treatment with lipopolysaccharide for rat brain and 
spleen (7,13). However, as the strongest 
expression was found in the gastrointestinal (GI) 
system, we explored a possible role of P2Y14 in 
the regulation of nutrient uptake and energy 
metabolism. 
 
EXPERIMENTAL PROCEDURES 
Cell culture, transfection and functional assays 
– For yeast experiments, the haploid 
Saccharomyces cerevisiae yeast strain MPY578t5 
(provided by Dr. Mark Pausch) was used for the 
expression of receptor constructs. Cells were 
transfected with plasmid DNA using 
electroporation as described (14). For expression 
in mammalian cells, COS-7 cells were grown in 
Dulbecco's modified Eagle's medium (DMEM 
supplemented with 10% (v/v) fetal bovine serum, 
100 units/ml penicillin and 100 μg/ml 
streptomycin) at 37°C in a humidified 5% CO2 
incubator. Transient transfection experiments of 
COS-7 cells with receptor constructs for cAMP 
inhibition measurements and for direct cAMP 
measurements (co-transfected with the chimeric G 
protein Gαsi5) were essentially performed as 
described previously (15). For measurements of 
dynamic mass redistribution (DMR) (16) HEK293 
cells were grown in DMEM/F12 medium 
supplemented with 10% (v/v) fetal bovine serum, 
100 units/ml penicillin and 100 μg/ml 
streptomycin at 37°C in a humidified 5% CO2 
incubator and transiently transfected with the 
receptor constructs and split onto fibronectin-
coated 384-well plates one day prior the assay. 
DMR measurements were performed with the Epic 
system (Corning, NY, US). 
For all transfection experiments the mouse and 
human P2Y14 coding sequence attached to an N-
terminal Hemagglutinin epitope and a C-terminal 
FLAG epitope was cloned into the mammalian 
expression vector pcD-ps. Additionally, for yeast 
experiments the mouse receptor was introduced 
into the yeast vector p416GPD. All control 
receptor plasmids were cloned with the described 
strategy. 
Generation of P2Y14-deficient mice - P2Y14-
KO mice were generated at TAKEDA Ltd. 
(Cambridge, United Kingdom) by targeted 
disruption of the mouse P2Y14 locus and ES-cell 
blastocyst injection. Thus, most part of the coding 
region of P2Y14 was exchanged by a ß-
galactosidase cassette harbouring an internal 
ribosome entry site (IRES) followed by a loxP-
floxed neomycin cassette (Fig. 1). After removal 
of the neomycin cassette, the resulting KO animals 
were bred with 129S6 animals and all studies were 
done on a mixed C57BL/6 x 129S6 background 
with predominance of 129S6. For experiments WT 
and KO littermates from intercrossed WT and KO 
parents were used. Genotyping of mice was carried 
out by PCR with the following primers: ß-gal 
sense (5’- 
AGAAGGCACATGGCTGAATATCGA -3’), 
forward (5`-
AGCTGCCGGACGAAGGAGACCCTGCTC-3’) 
and reverse (5’-
GGTTTTGGAAACCTCTAGGTCATTCTG-3’) 
in two separate PCR reactions (Fig. 1): 
forward/reverse to amplify WT allele (180 bp) and 
ß-gal sense/reverse to amplify KO allele (400 bp). 
The PCR conditions were 95°C for 3 minutes 
followed by 35 cycles with 45 sec 95°C, 60°C 30 
sec and 72°C for 1 min and a final amplification 
step of 72°C for 10 min.  
All mice were maintained in a specific 
pathogen-free barrier facility on a 12-h light/12-h 
dark cycle with ad libitum access to water and 
food. Experiments were performed according to 
the accepted standards of animal care and were 
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approved by the respective regional government 
agency of the State of Saxony, Germany (T27/11; 
T46/12; T07/13). 
Quantitative expression analysis - Several 
tissues were removed from 3 WT and 3 KO mice 
and RNA was isolated using TRIZOL (Sigma-
Aldrich, Taufkirchen, Germany) according to the 
manufacturer’s instructions. RNA quantity was 
measured with a spectrophotometer (Nanodrop ND 
1000, NanoDrop products, Wilmington, USA) and 
RNA quality was controlled by gel electrophoresis. 
For quantitative real time PCR (qPCR) 1 µg of 
total RNA was reversely transcribed (Superscript 
II RT, Invitrogen, Karlsruhe, Germany) using 
oligo-dT primers. qPCR was performed by 
Platinum SYBR Green qPCR SuperMix-UDG 
(Invitrogen) according to manufacturer’s 
instructions. Primers were designed for the intron-
flanking exons 1 and 2 sequences (Fig. 1) to 
exclude genomic contaminations (sense: 5’-
GAAGCCAGACGTGAAGGAGTT-3’; antisense: 
5’-CAGGAATCTCAAAGGCAAGCT-3’) 
resulting in a 156-bp product. qPCR was 
performed with the MX 3000P instrument (Agilent 
Technologies GmbH, Boeblingen, Germany) using 
the following protocol: 2 min at 50 °C, 2 min at 95 
°C, 40 cycles of 15 s at 95 °C and 30 s at 60 °C. A 
product dissociation curve was recorded to verify 
the presence of a single amplicon. Threshold cycle 
(Ct) values were determined during the 
exponential increase of the product in the PCR. 
After normalization to the house keeping gene ß2-
microglobulin calculated ∆Ct values were used to 
determine the relative expression of P2Y14. 
LacZ reporter gene assay - Tissue samples of 
several organs were prepared from WT and KO 
mice, covered in Tissue-Tek® (Sakura, Torrance, 
CA, USA) and snap frozen in liquid nitrogen. The 
organs were cryosectioned (10 µm) and fixed in 
acetone-methanol (1:1) solution. Sections were 
incubated with X-Gal staining solution at 30 °C 
overnight to detect the expression of the LacZ 
reporter gene via ß-galactosidase activity.  
Laboratory chemistry/histology/behavioral 
tests – Serum levels of electrolytes, metabolites, 
enzymes and hormones were analyzed in 3-month-
old WT and KO mice according to the guidelines 
of the German Society of Clinical Chemistry and 
Laboratory Medicine, using a Hitachi PPE-
Modular analyzer (Roche Diagnostics, Mannheim, 
Germany). Histological slices (5 μm) were 
prepared from organs being fixed in 4% 
formaldehyde solution and embedded in paraffin 
wax. Slices were stained with H&E. Blood cell 
counting from EDTA blood samples was 
performed automatically (ScilVet abc; Scil 
corporation, Viernheim, Germany). Open field and 
hot plate tests were performed as reported 
previously (17) using automated measuring 
technology (TSE Systems, Bad Homburg, 
Germany; Hot Plate 602001, TSE)).  
Gastrointestinal transit and contractility 
studies - A gastrointestinal emptying test was 
performed by oral application of 200 µl dye-
labeled non-absorbable liquid dextran blue (20 
mg/ml) to mice. Faeces were collected hourly for 8 
hours, vortexed with 300 µl phosphate buffered 
saline (PBS) and centrifuged at 13,000 rpm for 10 
min. The amount of hourly excreted dextran blue 
was measured photometrical at 620 nm in 
supernatants. Mice that showed no excretion for at 
least 2 hours were excluded from the experiment. 
For contractility studies mice were sacrificed by 
cervical dislocation. The intestine from mice was 
harvested and placed in ice-cold Krebs-Ringer 
buffer (KRB). One cm long equal segments of 
intestine were placed in 50-ml organ baths (37 °C) 
containing KRB solution and continuously gassed 
with 95% O2 and 5% CO2. To record the 
contractile activity, each intestine segment was 
connected to an isometric force transducer 
(MLT0201 Force Transducer; ADInstrumends 
GmbH, Spechbach, Germany). The basal tension 
was set to 10 mN. Several parameters like mean 
muscle tension, average tension maximum and 
minimum, average amplitude, rate of contractions 
and the area under the curve and the effect of 100 
µM UDP-glucose and 100 µM carbachol (positive 
control) were analyzed using Lab Chart software 
(ADInstruments). Data were normalized to 
recorded spontaneous activity and expressed in 
percentage.  
Hemodynamic parameters - Blood pressure and 
pulse were determined by non-invasive tail-cuff 
method using the BP-2000 Blood Pressure 
Analysis SystemTM (Visitech Systems, Apex, NC, 
USA). Following manufacturer’s instructions, 
mice were trained to the procedure each day for at 
least 5 days prior to the actual experiment. After 
the training period 10 measurements per day of 
each mouse on 5 consecutive days were 
performed. Systolic blood pressure, diastolic blood 
pressure, mean arterial pressure, and pulse were 
calculated from daily experiments for each mouse 
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and mean out of 10 animals per group was 
determined.  
Airway responsiveness - Lung resistance and 
dynamic compliance were measured by invasive 
plethysmography (emka TECHNOLOGIES, Paris, 
France) in response to inhaled UDP-glucose and 
methacholine (Sigma-Aldrich). Female mice were 
anesthetized (100 mg/kg ketamine and 10 mg/kg 
xylazine; Bayer Leverkusen, Germany), intubated 
and mechanically ventilated at a tidal volume of 
0.2 ml and a frequency of 150 breath/min. Baseline 
lung resistance, dynamic compliance, and 
responses to aerosolized saline (0.9 % NaCl) were 
measured first, followed by responses to 100 µM 
aerosolized UDP-glucose and increasing doses (10 
to 80 mg/ml) of aerosolized methacholine (18).  
Metabolic studies - 1-month-old mice were kept 
on standard (Ssniff M-Z: 5% sugar, 4.5% raw fat, 
34% starch, 22% raw protein) or western (Ssniff 
EF R/M TD88137: 32.8% sugar, 21.2% raw fat, 
14.5% starch, 17.1% raw protein) type diet (Ssniff 
GmbH, Soest, Germany) for 3 months. During this 
period body-weight development was monitored 
weekly. For glucose tolerance tests mice on a 
standard or a western type diet had been fasted 
overnight (15 h) and blood glucose levels were 
measured before (0 min), 20, 40, 60 and 120 min 
after oral application (80 mg) or intraperitoneal 
injection (2 mg/g body weight) of glucose. For 
insulin tolerance tests blood glucose levels were 
measured before (0 min) and 15, 30 and 60 min 
after intraperitoneal injection of human insulin 
(0.75 U/kg body weight). Blood glucose levels 
were determined by using an automated blood 
glucose meter (FreestyleLite, Abbott Diabetes 
Care Ltd., Oxon, UK). For insulin secretion tests 
mice fasted overnight were injected 
intraperitoneally with glucose (2 mg/g body 
weight) and blood samples were taken before (0 
min), 20, 40 and 60 min after injection. Serum 
insulin concentrations were measured using an 
Ultra Sensitive Mouse Insulin Elisa Kit (Crystal 
Chem, Inc., Downers Grove, IL, USA). All 
metabolic tests were performed with the same set 
of animals (one-week interval between the tests).  
Morphometric analysis - Pancreata from 5 WT 
and 5 KO mice fed with western type diet were 
fixed in 4 % formaldehyde and embedded in 
paraffin wax. Two longitudinal sections (4 µm) 
were generated every 100 µm of tissue. Each time, 
the first section was stained with H&E, the second 
immunostained for insulin with the avidin-biotin 
complex technique using anti-insulin monoclonal 
rabbit antibody (100 µg/ml, Cell Signalling, 
Millipore, Germany) and goat anti-rabbit 
secondary antibody (7.5 mg/ml, Vector Laboraties, 
Biozol Diagnostica, Germany). Both sections were 
photographed with a Zeiss Axioimager Z1 
microscope (Carl Zeiss Jena GmbH, Jena, 
Germany). Ten H&E stained sections per mouse 
were analyzed for number and area size of 
pancreatic islets using NIH ImageJ software. For 
determination of ß-cell area per islet the insulin-
positive area of at least 50 islets per mouse was 
calculated using NIH ImageJ software and related 
to the total islet area of the investigated slides.  
Isolation of pancreatic islets and insulin 
secretion experiments - Pancreatic islets were 
isolated as previously described (19-21). Briefly, 
mice were sacrificed by cervical dislocation and 
the pancreas was inflated by intraductal injection 
of ice-cold DMEM media containing 0.2 mg/ml 
(1.08 Wünsch Units) Liberase TL Research Grade 
(Roche Diagnostics GmbH, Mannheim, Germany). 
Distended pancreas was digested by shaking in a 
37 °C water bath for 17 minutes. Isolated islets 
were washed and picked under a stereomicroscope 
and incubated overnight at 37°C and 5% CO2 in 
RPMI-1640 media containing fetal bovine serum 
for insulin secretion studies. For dynamic insulin 
secretion studies groups of 50 pancreatic islets 
were placed in a perifusion chamber and 
continuously perifused with KRB for 30 min 
(flow: 1 ml/min). After this equilibration phase 
islets were perifused for 30 min with low glucose 
(2.8 mM) to determine the basal insulin release 
and then challenged for 30 min with 16.7 mM 
glucose or 16.7 mM glucose plus 100 µM UDP-
glucose. Samples of perifusate were collected 
every minute and insulin concentration was 
determined at indicated time points by Insulin 
AlphaLISA Kit (Perkin Elmer, Rodgau, Germany). 
For static incubation studies groups of 5 islets were 
placed in a 96-well plate. After a 30-minute 
equilibration period in KRB solution containing 
2.8 mM glucose, pancreatic islets were stimulated 
with KRB solution containing either 2.8 mM or 
16.7 mM glucose or 100 µM UDP-glucose in the 
presence of 16.7 mM glucose for 30 minutes. The 
supernatants were then collected for measurement 
of secreted insulin and islets were lysed in acid-
ethanol to extract the residual islet insulin (19,20). 
Insulin concentrations were determined by Insulin 
AlphaLISA Kit (Perkin Elmer).  
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RNA-sequencing of pancreatic islets - Total 
RNA from isolated pancreatic islets (10 male mice 
per genotype) was extracted by using TRIZOL 
(Sigma-Aldrich) according to the manufacturer’s 
instructions and RNA quantity was measured using 
a spectrophotometer (Nanodrop ND 1000). The 
RNA quality of all samples was analyzed on the 
Agilent 2100 bioanalyzer using the RNA 6000 
Nano Chip. cDNA libraries were generated using 
TruSeq RNA Sample Preparation Kits v2 
(Illumina, San Diego, CA, USA) according to the 
manufacturer’s protocol. Indexed islet libraries of 
good quality were pooled and used for sequencing 
on two flow cell lanes on an Illumina HiScanSQ 
System. To confirm base calling correctness the 
raw data passed a quality check using FastQC 
software. It revealed low PHRED-scale scores at 
the 3’ end of the 101 bp long reverse reads. These 
reads were trimmed to a size of 80 bp. Then, reads 
were assigned to the individual animals using the 
ligated adapter indices. Further, the samples 
proceeded filtering to trim the adapter sequences 
and remove low-quality reads which were shorter 
than 60 bp or contained more than five bases with 
a quality score below 15 (PHRED-scale). The 
paired-end reads were mapped to the reference 
mouse genome (July 2007 NCBI37/mm9) with 
Ensembl v66 annotations using Tophat 1.3.3. (22), 
which aligns reads using Bowtie (version 0.9.9). 
Mitochondrial reads and reads which did not map 
uniquely to a genome position were excluded. 
FPKM (fragments per kilobase of transcript per 
million mapped reads) values were calculated 
using Cufflinks 1.3.0 (22,23). Analysis of 
differential expression was performed using 
DESeq software package (24). Only genes that 
were expressed at least in 10 animals were 
considered for analysis. Functional enrichment 
analysis of differentially expressed genes (P < 
0.05) was determined using ToppGene Suite (25). 
 
RESULTS AND DISCUSSION 
Although widely expressed, previous studies on 
P2Y14 mainly focused on immune cells and its 
relevance in inflammatory responses (7-12,26). 
Initial evidence indicates a role of P2Y14 in UDP-
glucose-mediated chemotaxis of neutrophils and 
bone marrow cells, mast cell degranulation and 
proliferation of T cells (9,10,27,28). However, 
studies suggest that UDP-glucose can mediate 
cellular effects via P2Y14-dependent and -
independent pathways (29-31). To identify 
phenotypes related to the lack of P2Y14 function, 
this GPCR gene was removed by targeted deletion 
and replacement with a LacZ reporter gene. The 
P2Y14-deficient offspring was vital and fertile. 
This is consistent with a very recent study 
investigating P2Y14 relevance in embryonic 
lethality after radiation (32). Except for a 
significantly higher spleen weight (suppl. Table 
S1) and slightly increased blood pressure (suppl. 
Table S1) no obvious differences in genotype 
distribution, breeding, growth, gross morphology, 
histology, laboratory chemistry and behavior were 
detected on primary inspection compared to WT 
mice (suppl. Table S1). 
 
P2Y14 is widely expressed in mouse tissues – 
We next took advantage of the introduced LacZ 
reporter construct and monitored ß-galactosidase 
activity in P2Y14-deficient mouse tissues. Whereas 
WT control tissues showed no specific staining, ß-
galactosidase-positive staining was found in 
uterus, bronchioles, blood vessels, pancreas, 
salivary glands (Figs. 2A and 3), and immune 
cells. Interestingly, staining in the GI tract was 
positive only in a subpopulation of smooth muscle 
cells (Fig. 2B/C). In all parts of the GI tract smooth 
muscle cells of the thin layer of the muscularis 
mucosae were ß-galactosidase positive (Fig. 
2B/C). From the ileum to the rectum a 
subpopulation of smooth muscle cells within the 
circular smooth muscle layer showed positive 
staining (Fig. 2B/C). In the rectum also the 
longitudinal smooth muscle layer displayed 
intensive ß-galactosidase activity (Fig.2B/C). Co-
staining of c-kit, which is a marker of Cajal cells 
and mast cells in the GI tract (33,34), revealed no 
obvious overlap with the ß-galactosidase-positive 
structures (data not shown). In contrast the ß-
galactosidase staining was partly reminiscent of 
the reported divergent reactivity of intestinal 
smooth muscle cells with characteristic smooth 
muscle cell markers (i.e. alpha-smooth muscle 
actin (ASMA), gamma-smooth muscle actin 
(GSMA)) (35). To our best knowledge, there is no 
other smooth muscle subtype which may 
correspond to the cells marked by the P2Y14-
reporter construct.  
Further assessment of the LacZ expression in 
pancreatic tissue showed ß-galactosidase-positive 
staining in exocrine and endocrine glandular 
structures (Fig. 3). Interestingly, cells next to the 
pancreatic acini (Fig. 3A-C) and myoepithelial 
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cells of the salivary glands (Fig. 2A) were stained. 
Investigations addressing the specific functions of 
the myoepithelial cells are ongoing.  
One should keep in mind that P2Y14-promoter-
driven ß-galactosidase-expression was monitored 
in KO mice and may reflect transcript over- or 
even non-physiological expression due to P2Y14 
deficiency. To address this issue, we measured 
expression of the 5’UTR region of WT and KO 
P2Y14 gene transcripts, which were structurally 
similar in both WT and KO animals, by qPCR in a 
number of tissues (Fig. 4). As presented in Fig. 4B, 
ΔCt values of transcript expression showed a high 
correlation between WT and KO in all tissues (r2 = 
0.9058). This almost excluded compensatory or 
reactive LacZ expression effects following P2Y14 
deficiency in KO tissues. Both data sets revealed 
that P2Y14 is widely expressed in mouse tissues 
with high expression levels in pancreas, salivary 
glands, brain, lung and parts of the gastrointestinal 
tract and lowest expression in liver (Fig. 4). This is 
in accord with previous findings in human and rat 
tissues (3,7,8) but now adds that distinct smooth 
muscle cells and immune cells are the cellular 
basis of broad expression levels previously found 
in qPCR and Western blot analyses. 
 
P2Y14 deficiency alters smooth muscle 
functions in GI tract and airways – To study the 
consequences of P2Y14 deficiency in the different 
smooth muscle containing organs we tested several 
GI tract and bronchial tract functions. A previous 
study in rat revealed high P2Y14 mRNA levels and 
found UDP-glucose-dependent increase in the 
baseline muscle tension of the forestomach. 
However, comparison of WT und P2Y14-deficient 
mice revealed no differences in gastric emptying 
(30). Because we found no effect of UDP-glucose 
(up to 1 mM) on basal and carbachol-stimulated 
and electric-stimulated contraction of isolated 
small intestine and colon (data not shown), we 
speculated that the contribution of P2Y14 is more 
distinct and may present its significance only when 
the entire GI passage is observed. Thus, a dye-
labeled dextran was applied to mice orally and the 
excretion in faeces was measured hourly. In 
comparison to WT animals the expulsion of 
dextran blue was significantly delayed in KO mice 
(Fig. 5). Interestingly, more KO animals (5 KO vs. 
1 WT) had to be excluded from analysis according 
to our exclusion criterion (see Experimental 
Procedures). 
P2Y14-reporter gene expression was also found 
in smooth muscle cells of bronchioles (Fig. 2A). 
To dissect its function in respiratory tract invasive 
plethysmography tests were performed. Although 
UDP-glucose had no effect on respiratory 
functions tested, KO mice showed significantly 
higher dynamic compliance in response to 
increasing inhaled doses of methacholine (Fig. 6). 
One should note the expression of P2Y14 in 
mainly venous blood vessels (Fig. 2A) and 
significant increases in blood pressure and heart 
rate of P2Y14-deficient mice (suppl. Table S1). 
There is some evidence that P2Y14 may have 
vasocontractile function on arteries (36) but P2Y14 
expression in smooth muscle cells in arteries is 
controversially discussed (37,38). We found some 
ß-galactosidase positive arteries only in lung and 
CNS (circulus arteriosus Willisii) (data not 
shown). Future studies will address if there is a 
physiological link between P2Y14 expression in 
the vascular system and hemodynamic functions. 
In sum, we show that P2Y14 is highly expressed 
in a distinct subset of smooth muscle cells. P2Y14 
expressed on those cells modulate contractile 
function of the GI and the bronchial tracts. 
 
P2Y14 deficiency results in reduced glucose 
tolerance – Our phenotype screen also included 
basic metabolic tests. Following oral glucose 
application KO mice showed significantly higher 
transient blood glucose levels (Fig. 7A). To 
differentiate whether the enteral glucose resorption 
was increased in KO mice due to the prolonged 
gastrointestinal emptying (see above), 
intraperitoneal glucose tolerance tests were 
performed. Blood glucose levels were also 
increased in KO mice following intraperitoneal 
glucose injection (Fig. 7B) excluding differences 
in enteral glucose resorption. To study whether 
high caloric nutrition can aggravate the phenotype 
found in KO mice, 4-week-old mice were kept on 
a western type diet for 3 months. WT and KO mice 
gained significantly body weight under the western 
type diet. But whereas there were no alterations in 
body weight development between WT and KO 
mice kept on standard diet, KO mice fed the 
western diet gained significantly less weight (KO: 
178 ± 15% vs. WT: 196 ± 23%, P < 0.05). 
However, detailed analysis of serum cholesterol 
and TAG levels in all lipoprotein fractions 
revealed no differences between WT and KO mice 
fed a western type diet (suppl. Table S1). 
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Interestingly, glucose tolerances following oral and 
intraperitoneal glucose application were 
significantly reduced in KO mice kept under 
western type diet (Fig. 7C/D).  
Next, we performed insulin tolerance tests to 
evaluate whether the higher glucose levels 
observed in KO mice in the oGTT were because of 
altered insulin sensitivity. There were no 
differences in the decline of blood glucose levels 
following intraperitoneal insulin injection between 
WT and KO mice (Fig. 8A). Similar results were 
found for mice kept on western type diet (Fig. 8B) 
although both genotypes showed lower insulin 
sensitivity as a result of higher body weight due to 
high caloric nutrition. As insulin sensitivity did not 
account for altered oGTT in KO mice we analyzed 
insulin levels in WT and KO mice during 
intraperitoneal glucose tolerance tests. On chow 
diet, KO mice (16 weeks old) tended to have lower 
serum insulin levels after intraperitoneal glucose 
application (Fig. 8C). Interestingly, after 12 weeks 
of western type diet glucose-stimulated insulin 
secretion of KO mice was significantly lower 40 
and 60 min after intraperitoneal glucose injection 
compared to WT mice (Fig. 8D).  
In a recent paper, Xu et al (39) showed 
improved glucose tolerance in P2Y14-deficient 
mice fed with a high-fat diet due to an elevated 
insulin sensitivity e.g. of the liver. This is in 
contrast to our data where insulin sensitivity of KO 
and WT mice was not different (Fig. 8A/B). It was 
argued that reduced macrophage infiltration and 
hepatic inflammation account for improved hepatic 
insulin sensitivity (39). As in our study (Fig. 
8C/D), Xu et al (39) found reduced serum insulin 
levels after glucose administration in KO mice. 
This important finding remained unappreciated in 
their study and other pathophysiological 
mechanisms were not considered. In a more 
reasonable scenario, lower insulin levels result in a 
reduced hepatic steatosis, as found in (39) under 
high-fat diet. In fact, the differential expression of 
genes involved in lipid and glycogen metabolism 
in liver, as found in (39), can be interpreted as a 
consequence of lower insulin levels. It is well 
known that insulin stimulates the expression of 
lipogenic enzymes such as fatty-acid synthase and 
acetyl-CoA carboxylase and inhibits the 
transcription of gluconeogenic enzymes such as 
glucose-6-phosphatase and phosphoenolpyruvate 
carboxykinase (40). Thus, reduced insulin 
secretion may also result in reduced weight gain 
following high caloric nutrition as seen in our 
P2Y14-deficient mice kept under western type diet. 
The hepatic inflammation is most likely secondary 
to the alimentary hepatic steatosis found in (39). 
Since the western type diet we used does not 
significantly differ from the high-fat diet (see 
Experimental Procedures) Xu et al fed the mice 
(26.3% carbohydrates, 34.9% fat, 26.2% protein) 
we further focused on the reason for the lower 
blood insulin levels which were seen already in 
animals fed with standard chow.  
 
Components involved in insulin release are 
differentially expressed in P2Y14-deficient islets – 
Our functional data pointed towards a lower 
pancreatic insulin secretion after intraperitoneal 
glucose administration. High expression of P2Y14 
was noticed in the exocrine pancreas (Figs. 3 and 
4) but also in pancreatic islets (Fig. 3D). We first 
performed morphometric analyses in H&E and 
insulin immunohistochemistry stained slices in 
P2Y14-KO mice. Neither the number nor the size 
of the pancreatic islets differed between WT and 
KO mice (Fig. 9A/C). Also, the insulin 
immunopositive areas were similar in both 
genotypes, suggesting no gross morphological 
abnormalities in islet development (Fig. 9B/D). 
Since P2Y14-deficient islets did not show 
obvious morphological differences we screened for 
those at a molecular level. Thus, mRNA 
expression in WT and KO pancreatic islets was 
analyzed in a transcriptome-wide approach using 
RNA-sequencing. Approximately 13 million reads 
per animal were analyzed. As expected, insulin, 
glucagon, somatostatin and SUR1/Kir6.2 
transcripts were highly expressed in islets of both, 
WT and KO mice. In line with the data from 
immunohistochemistry there was no difference in 
insulin mRNA expression levels between WT and 
KO (suppl. Table S2). The expression of P2Y14 
gene was significantly reduced in KO mice (suppl. 
Table S2), but one should note that detected P2Y14 
transcripts in the KO islets represented mRNA 
sequences of the 5’UTR region and not of the 
coding region (Fig. 1). In line with our RNASeq 
data, also qPCR analysis (∆Ct = 7.64 ± 0.55), ß-
galacosidase staining of pancreatic tissue (Fig. 3) 
and other studies (41) clearly demonstrate P2Y14 
expression in pancreatic islets. 
815 genes were found differentially expressed 
between WT and KO mice (329 transcripts 
downregulated, 486 transcripts upregulated, P < 
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0.05, the complete list can be provided on request). 
Functional enrichment analysis of differentially 
expressed genes disclosed several GO (Gene 
Ontology) categories related to protein synthesis, 
signaling pathways and hormone secretion (suppl. 
Table S3). Since serum insulin levels were reduced 
in KO mice we mainly focused on genes known to 
be related to glucose sensing, insulin exocytosis 
and its modulation. Selected components involved 
in insulin release and their changes in transcript 
levels are schematically given in Figure 10. 
Glucose uptake through the glucose transporter 
2 (GLUT2) is a first key step in regulation of 
insulin release (42) (Fig. 10). The expression of 
GLUT2 (Slc2a2) was significantly downregulated 
in KO mice and may indicate a possibly reduced 
glucose-sensing or -responding ability of the islets.  
The major trigger of insulin vesicle exocytosis 
is an increase in intracellular Ca2+ (42) and cAMP 
and protein kinase A (PKA) activity are known to 
amplify insulin exocytosis (43). In the classical 
model of GPCR-modulated insulin release, Gq 
(Ca2+) and Gs (cAMP) activating receptors 
promote insulin release, whereas Gi/o protein-
coupled receptors reduce insulin release by 
inhibiting adenylyl cyclases and reducing cAMP 
levels in β-cells. Indeed, several components 
involved in receptor- and ion channel-controlled 
intracellular Ca2+ levels were downregulated in 
islets of KO mice, among them the subunits 
CACNA1C and CACNA1H of the voltage-
dependent Ca2+ channels (VDCC), the endoplasmic 
reticulum IP3 receptor (ITPR1), cAMP-degrading 
phosphodiesterases PDE1C and PDE4D (44), 
several GPCR known to modulate insulin release 
such as the free-fatty acid receptor FFAR1 (45), 
calcium-sensing receptor (CASR), GLP1 receptor 
(GLP1R), GPR119, somatostatin receptors SSTR1 
and SSTR2 (and their agonist somatostatin) 
(41,46). 
In sum, transcriptome data showed significant 
changes in relevant components of glucose 
sensing, Ca2+-triggered and GPCR-modulated 
insulin release pathways in islets of P2Y14-
deficient mice which suggested changes in islet 
function of KO animals. 
 
Reduced insulin release from pancreatic islets 
of P2Y14-deficient mice – It is almost impossible to 
functionally analyze all components found to be 
differentially expressed between WT und KO at 
both, their individual level and their signaling 
network level. Therefore, we studied insulin 
secretion, as one integral islet function, in 
perifused and static treated islets in vitro. Although 
intracellular insulin content was similar in lysed 
islets isolated from WT and KO mice (Fig. 11A), 
the insulin release following stimulation with low 
(2.8 mM) and high glucose (16.7 mM) during a 30 
min incubation was significantly reduced in islets 
lacking P2Y14 (Fig. 11B/C). To study the kinetics 
of insulin release, isolated islets were placed in a 
perifusion chamber and continuously perifused 
with KRB solution containing different glucose 
concentrations. The initial insulin release peak and 
the sustained insulin release were significantly 
reduced in KO islets stimulated with a high 
glucose concentration (16.7 mM) (Fig. 11D). 
These data clearly demonstrated that P2Y14 
deficiency has a negative impact on glucose-
dependent insulin release from isolated pancreatic 
islets and confirmed our in vivo findings. 
Since P2Y14 couples to Gi/o proteins, inhibits 
adenylyl cyclases and mobilizes intracellular Ca2+ 
(11,28) most probably via release of Gβγ dimers 
from Gi proteins (47), one would expect that loss 
of this gene should rather improve glucose-
mediated insulin release from β-cells. However, 
UDP-glucose alone was neither able to 
significantly release insulin nor significantly 
reduce glucose-induced insulin release from 
isolated islets (see Fig. 11). Therefore, we re-
evaluated the agonistic properties of UDP- and 
UDP-glucose at the mouse and human P2Y14 with 
different methods in vitro. Techniques using 
chimeric G proteins in yeast and mammalian 
heterologous expression systems showed high 
basal activity of P2Y14 and some minor UDP- and 
UDP-glucose-mediated responses (Fig. 12A, Table 
1). However, UDP and UDP-glucose did not 
significantly activate P2Y14 in classic cAMP 
inhibition assay (Table 1) and label-free DMR 
(Fig. 12B), whereas the Gi-coupled neuropeptide 
Y receptor Y2 showed robust agonist-mediated 
signals in all tests. At the current stage, UDP and 
UDP-glucose show weak agonistic activity at 
P2Y14 in functional assays using chimeric G 
proteins (2). Label-free and classic second 
messenger assays as well as our in vivo data with 
knock-out mice do not provide evidence for 
physiological activities of UDP and UDP-glucose 
at P2Y14. Further studies using clear-cut controls 
(e.g. gene-deficient animals) are required to finally 
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prove or disprove UDP-Glc and UDP as 
physiological agonists for P2Y14. 
The cell type within Langerhans islets, where a 
specific GPCR is expressed, determines its 
function on insulin exocytosis. Currently, the cell 
type(s) of pancreatic islets expressing P2Y14 is 
unknown. Further, the effect of a given GPCR on 
insulin release apparently not only depends on its 
G protein-coupling mode. Thus, Gq protein-
coupled receptors such as the GnRH receptor 
inhibits insulin release whereas the exclusively Gi 
protein-coupled cannabinoid receptor type 1 and 
the melanin-concentrating hormone receptor 
stimulate insulin release from islets (41). The most 
abundant somatostatin receptor SSTR3 (see suppl. 
Table S2), which is Gi/o protein-coupled, has no 
significant effect on insulin release (41). As for 
several GPCR expressed in pancreatic islets (41) 
the specific signaling pathway how P2Y14 
modulates gene expression and functions of islets 
needs to be studied further. 
CONCLUSION 
Mice with P2Y14 deficiency present a rather 
mild phenotype under SPF (specific pathogen free) 
conditions. However, our studies revealed 
involvement of P2Y14 in GI tract emptying and 
glucose homeostasis regulation. The lack of P2Y14 
function reduced intestine passage and glucose-
stimulated insulin release from pancreatic islets in 
vitro and in vivo. It is of interest that several 
GPCR, e.g. GLP1R, GPR39, M3 muscarinic 
receptor and galanin receptor, modulate both, GI 
motility and glucose-induced insulin secretion (48-
51). For P2Y14 it is currently unclear whether this 
GPCR realizes its effect by acute activation of its 
signaling cascade or during islet ontogenesis. The 
gross transcriptome changes found in P2Y14-
deficient islets may also suggest a more complex 
alteration of the expression profile indicating a role 
of P2Y14 in subdifferentiation of islets cells. 
Indeed, some genes which are involved in 
differentiation and maturation of pancreatic islet 
cell types (e.g. MAFA, MAFB, REG2) (52-54) are 
differentially expressed in the islets isolated from 
P2Y14-deficient mice (Fig. 10). Although we did 
not find differences in gross islet morphology and 
islet size distribution (Fig. 9), there is evidence that 
e.g. pancreatic β-cells are not homogenous but 
rather present functionally different subpopulations 
with distinguishable functionality (55,56). Thus, 
P2Y14-mediated signaling may be one signal that 
modulates distinct functionalities of islet cells. 
Since Langerhans islets derived from pancreatic 
ductal cells during ontogenesis and P2Y14 
expression was morphologically also found in the 
exocrine pancreas (Fig. 3), more detailed studies 
should focus on the relevance of P2Y14 in pancreas 
development. Further studies with conditional β-
cell-specific KO mice can help to differentiate 
between acute and adaptive effects of P2Y14 
deficiency. Nevertheless, our findings identify 
P2Y14 as a novel modulator of insulin secretion. 
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FIGURE LEGENDS 
FIGURE 1. Generation of a P2Y14-deficient mouse strain and P2Y14 qPCR design. 
P2Y14-deficient mice were generated at TAKEDA Ltd.. The coding sequence was partly replaced by an 
ECMV-IRES / ß-galactosidase cassette followed by a loxP-floxed neomycin selection cassette. We 
removed neomycin cassette by breeding with EIIa-Cre mice and successful removal was verified by PCR. 
For qPCR a primer pair matching to exon 1 and 2 was designed. Genotyping of mice was performed as 
described in Experimental Procedures with primers indicated as: for, rev and ß-gal s. 
FIGURE 2. Detection of bacterial LacZ reporter gene via ß-galactosidase activity in cryosections of 
selected organs. 
To monitor the expression of P2Y14 in vivo at the cellular level a transgenic KO mouse was generated by 
replacement of the P2Y14–coding region with an expression cassette harboring an internal ribosome entry 
site and the bacterial LacZ reporter gene under control of the endogenous P2Y14 promoter. Sites of LacZ 
expression were located in cryosections using X-Gal, and counterstained with nuclear fast red. (A) 
Whereas no ß-galactosidase activity was detected in WT mice, KO mice showed intensive ß-galactosidase 
staining several other smooth muscle or contractile cell-containing organs. A indicates arterial vessel, V 
indicates venous blood vessel. (B) ß-galactosidase staining in the GI tract was only positive in a 
subpopulation of smooth muscle cells. (C) The expression of P2Y14 in certain muscle layers throughout 
the GI tract is schematically given.  
FIGURE 3. Detection of bacterial LacZ reporter gene in cryosections of pancreatic tissue. 
(A) Expression of LacZ reporter gene in exocrine and endocrine parts of the pancreas. The enlarged 
picture details show the expression in the acini (B/C) and in cells of the islet (D). 
FIGURE 4. P2Y14 transcript and P2Y14-promoter-driven LacZ gene expression in mouse tissues. 
Total RNA was extracted from several tissues from WT and P2Y14-KO mice (n=3) and mRNA levels of 
either P2Y14 or LacZ transcripts were determined by SYBR Green qPCR analysis. Primers were designed 
for the intron-flanking exons 1 and 2 (see Fig. 1). Expression data are shown as ∆Ct values normalized to 
the house keeping gene ß2-microglobulin. (A) qPCR analysis shows a widespread receptor distribution 
with high expression levels in pancreas, salivary glands, brain and parts of the gastrointestinal tract and 
lowest expression in liver. Data shown as mean ± SEM. (B) Expression of bacterial LacZ reporter gene in 
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KO mice correlates (r2=0.9058) with the expression of P2Y14 in WT mice. Dashed line indicates the 95 % 
confidence interval. 
FIGURE 5. P2Y14-deficient mice showed a delayed gastrointestinal emptying. 
A dye-labeled dextran was applied to mice orally and the excretion in faeces was measured hourly. The 
excretion of blue dextran is shown relative to the total excreted blue dextran after 8 hours. Five KO mice 
but only one WT animal had to be excluded from analysis according to our exclusion criterion (see 
Experimental Procedures). OD620 nm (∆ 8h) = 0.8770 ± 0.0630 for WT and OD620 nm (∆ 8h) = 0.5636 ± 0.0731 
for KO mice were set to 100 % respectively. Data shown as mean ± SEM. * P < 0.05; ** P < 0.01; *** P 
< 0.001; Student’s t-test 
FIGURE 6. Airway responsiveness is reduced in P2Y14-deficient mice. 
Lung resistance (A) and dynamic compliance (B) were measured by invasive plethysmography (emka 
TECHNOLOGIES) in response to inhaled UDP-glucose and increasing doses of methacholine. Data 
shown as mean ± SD. Baseline values (set to 100 %) were: lung resistance 1.28 ± 0.41 mmHg x s/ml for 
WT mice and 1.11 ± 0.34 mmHg x s/ml for KO mice, dynamic compliance 0.84 ± 0.56 ml/mmHg for WT 
and 0.72 ± 0.43 ml/mmHg for KO mice; * P < 0.05; Student’s t-test. 
For statistic analysis of the entire methacholine test a paired two-tailed t-test (marked by a long line) was 
performed (P = 0.0105 for dynamic compliance).  
FIGURE 7. P2Y14-deficient mice show reduced glucose tolerance. 
Glucose tolerance tests were performed either by oral application (A, C) of 80 mg glucose or by 
intraperitoneal (B, D) glucose injection (2 mg/g body weight) to overnight fasted male mice kept under 
standard (A, B) or western (C, D) type diet. Blood glucose levels shown as mean ± SD. * P < 0.05; ** P < 
0.01; *** P < 0.001; Student’s t-test 
FIGURE 8. P2Y14-deficient mice showed diet-dependent lower serum insulin levels after glucose 
administration. 
First, blood glucose levels were measured in an insulin tolerance test (ITT) after intraperitoneal injection 
of insulin (0.75 U/kg body weight) in male mice kept under standard (A) and western (B) type diet. Blood 
glucose levels before insulin application (set to 100 %) were 4.9 ± 0.6 mmol/l for WT and 5.8 ± 1.0 
mmol/l for KO mice fed with standard diet, and 5.6 ± 0.7 mmol/l for WT and 6.1 ± 0.9 mmol/l for KO 
mice kept under western type diet. Data shown as mean ± SD. * P < 0.05; Student’s t-test. Then, serum 
insulin levels were determined before (0 min) and 20, 40 and 60 min after intraperitoneal glucose injection 
(2 mg/g of body weight) in male mice kept under standard (C) and western type (D) diet. Data shown as 
mean ± SEM. ** P < 0.01; Student’s t-test 
FIGURE 9. Normal architecture of pancreatic islets in P2Y14-deficient mice. 
(A) Representative H&E stained pancreatic section used for morphometric analyses. (B) Insulin 
immunohistochemistry of representative pancreatic islets. (C) The number and area of islets in 10 serial 
slices of pancreatic tissue were determined using NIH ImageJ Software. The number of islets was 141 ± 
17 in WT and 157 ± 11 in KO mice. (D) β-cell mass was determined as ratio of insulin positive area to 
total pancreatic islet area. Data shown as mean ± SD.  
FIGURE 10. Signaling pathways involved in insulin secretion from β-cells.  
Several components involved in insulin release from pancreatic islets are shown. P2Y14 deficiency led to 
increased (green) and decreased (red) transcription of several genes compared to islets from WT mice. 
Detailed data from RNASeq experiments are given in supplemental Table S2 and Table S3. A list of all 
differentially expressed transcripts can be provided on request. 
FIGURE 11. Impaired insulin secretion of isolated pancreatic islets of P2Y14-deficient mice. 
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For cumulative insulin measurements (A-C), pancreatic islets were isolated from WT and KO male mice 
and incubated 30 min with KRB solution containing 2.8 mM glucose, 16.7 mM glucose or 16.7 mM 
glucose plus 100 µM UDP-glucose (n=5-7). Insulin levels of lysed islets (A), in the supernatants (B) and 
the ratio of both (C) are shown. For kinetic insulin measurements (D), pancreatic islets were isolated from 
WT and KO male mice and continuously perifused with KRB solution containing 2.8 mM glucose, 16.7 
mM glucose, or 16.7 mM glucose plus 100 µM UDP-glucose. Insulin levels shown as mean ± SEM. * P < 
0.05; ** P < 0.01; *** P < 0.001; Student’s t-test 
FIGURE 12. Testing UDP-glucose and UDP at P2Y14 in yeast and mammalian cells. 
(A) Genetically engineered yeast cells (57) transformed with the indicated receptor constructs were 
analyzed without (basal) and with agonist (10 µM). Receptor activation was measured after 40 hours as 
growth of yeast cells in histidine-depleted medium by recording the optical density (OD) at 600 nm. Data 
(mean ± SD) from two independent experiments (in triplicate) are shown. (B) Transiently transfected 
HEK293 cells (P2Y14, neuropeptide Y receptor Y2) were seeded in 384-well plates the day prior DMR 
measurements (16). Cells were challenged with indicated concentrations of the corresponding agonist 
(UDP, UDP-glucose, NPY) and wavelength shift (in pm) was monitored. Each receptor stimulation curve 
was first corrected against own buffer control (basal) and second, against mock-transfected cells 
stimulated with the respective agonist. Data from three independent experiments (mean ± SEM) were 
summarized, each performed in quadruplicate. 
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TABLES 
TABLE 1. Functional measurements of mouse and human P2Y14 receptors. 
Mouse and human P2Y14 constructs and two other Gi-coupled receptors as controls were transfected for 
cAMP inhibition and direct cAMP measurements (via a chimeric Gɑsi5 protein) as described in 
Experimental Procedures. For inhibition of cAMP, transfected COS-7 cells were stimulated either with 5 
µM Forskolin (FSK) or together with the indicated agonists for 15 minutes. Forskolin-stimulated values of 
each receptor were set 100% and % of inhibition due to the agonist stimulation was calculated for each 
receptor. Forskolin-stimulated cAMP values for each receptor and mock transfected cells (in nM) are 
given in brackets. Basal cAMP levels prior Forskolin-stimulation for mock-transfected cells were 0.88 ± 
0.57 nM. The number of assays is indicated in each column. All assays were performed in triplicates. 
cAMP inhibition cAMP (nM) 
 % of FSK stimulation  cotransfected Gαsi5 
transfected construct agonist (n=10) (n=4) 
mock 
FSK/basal 100 (7.78 ± 1.29) 2.71 ± 1.42 
UDP 96.93 ± 9.53 2.95 ± 2.22 
UDP-Glc 104.06 ± 18.13 3.12 ± 1.18 
NPY 106.08 ± 27.75 3.12 ± 1.44 
CCh 92.13 ± 17.59 2.67 ± 1.76 
mouse P2y14 
FSK/basal 100 (8.96 ± 1.92) 7.22 ± 1.99 
UDP 103.37 ± 22.91 8.10 ± 2.18 
UDP-Glc 93.81 ± 21.66 9.20 ± 2.05 
human P2Y14 
FSK/basal 100 (8.73 ± 3.12) 7.49 ± 3.00 
UDP 99.10 ± 18.56 8.04 ± 3.26 
UDP-Glc 98.88 ± 21.47 8.86 ± 3.50 
mouse Y2R 
FSK/basal 100  (11.54 ± 3.21) 4.18 ± 0.98 
NPY 64.49 ± 15.09 12.10 ± 3.24 
human M2R 
FSK/basal 100 (12.09 ± 3.30) 4.93 ± 0.56 
CCh 80.00 ± 21.28 11.34 ± 2.96 
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